<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">medRxiv</journal-id><journal-id journal-id-type="pmc-domain-id">3854</journal-id><journal-id journal-id-type="pmc-domain">medrxiv</journal-id><journal-id journal-id-type="publisher-id">MEDRXIV</journal-id><journal-title-group><journal-title>medRxiv</journal-title></journal-title-group><publisher><publisher-name>Cold Spring Harbor Laboratory Preprints</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10055465</article-id><article-id pub-id-type="pmcid-ver">PMC10055465.1</article-id><article-id pub-id-type="pmcaid">10055465</article-id><article-id pub-id-type="pmcaiid">10055465</article-id><article-id pub-id-type="pmid">36993749</article-id><article-id pub-id-type="doi">10.1101/2023.03.09.23286958</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The genetic architecture of pain intensity in a sample of 598,339 U.S. veterans</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Toikumo</surname><given-names initials="S">Sylvanus</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vickers-Smith</surname><given-names initials="R">Rachel</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jinwala</surname><given-names initials="Z">Zeal</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="H">Heng</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saini</surname><given-names initials="D">Divya</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hartwell</surname><given-names initials="E">Emily</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Venegas</surname><given-names initials="MP">Mirko P.</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sullivan</surname><given-names initials="KA">Kyle A.</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="K">Ke</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jacobson</surname><given-names initials="DA">Daniel A.</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gelernter</surname><given-names initials="J">Joel</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rentsch</surname><given-names initials="CT">Christopher T.</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><collab>Million Veteran Program</collab></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stahl</surname><given-names initials="E">Eli</given-names></name><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cheatle</surname><given-names initials="M">Martin</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="H">Hang</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Waxman</surname><given-names initials="SG">Stephen G.</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Justice</surname><given-names initials="AC">Amy C.</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref><xref rid="A9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kember</surname><given-names initials="RL">Rachel L.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kranzler</surname><given-names initials="HR">Henry R.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Mental Illness Research, Education and Clinical Center, Crescenz VAMC, Philadelphia, PA, USA</aff><aff id="A2"><label>2</label>Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA</aff><aff id="A3"><label>3</label>Department of Epidemiology, University of Kentucky College of Public Health; Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington, KY, USA</aff><aff id="A4"><label>4</label>Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA</aff><aff id="A5"><label>5</label>Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA</aff><aff id="A6"><label>6</label>Yale University School of Medicine, New Haven, CT, USA</aff><aff id="A7"><label>7</label>London School of Hygiene &amp; Tropical Medicine, London, UK</aff><aff id="A8"><label>8</label>Regeneron Genetics Center, Tarrytown, NY, USA</aff><aff id="A9"><label>9</label>Yale University School of Public Health, New Haven, CT, USA</aff><author-notes><corresp id="CR1"><bold>Corresponding author:</bold> Henry R. Kranzler, MD, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. <email>kranzler@pennmedicine.upenn.edu</email></corresp><fn fn-type="con" id="FN1"><p id="P1">Contributions</p><p id="P2">S.T conducted the main analyses and drafted the manuscript. R.V.S conducted phenotype-related analyses. Z.J and H.X conducted downstream analyses. D.S annotated gene findings. M.P.V and K.S helped conduct analyses. R.V.S, Z.J, H.X, D.S, E.H, M.P.V, K.S, K.X, J.G, D.A.J, C.T.R, M.C, E.S, and S.G.W helped to write the manuscript. A.C.J obtained funding to support the project and helped to write the manuscript. R.L.K supervised the analyses and helped to write the manuscript. H.R.K conceived the project, obtained funding to support it, and helped to supervise the analyses and write the manuscript. All authors reviewed and approved the final version of the manuscript</p></fn></author-notes><pub-date pub-type="epub"><day>13</day><month>3</month><year>2023</year></pub-date><issue-id pub-id-type="pmc-issue-id">432303</issue-id><elocation-id>2023.03.09.23286958</elocation-id><pub-history><event event-type="pmc-release"><date><day>29</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>30</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-18 18:25:34.380"><day>18</day><month>02</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License</ext-link>, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihpp-2023.03.09.23286958v1.pdf"/><self-uri content-type="pdf">nihpp-2023.03.09.23286958.pdf</self-uri><abstract id="ABS1"><p id="P3">Chronic pain is a common problem, with more than one-fifth of adult Americans reporting pain daily or on most days. It adversely affects quality of life and imposes substantial personal and economic costs. Efforts to treat chronic pain using opioids played a central role in precipitating the opioid crisis. Despite an estimated heritability of 25-50%, the genetic architecture of chronic pain is not well characterized, in part because studies have largely been limited to samples of European ancestry. To help address this knowledge gap, we conducted a cross-ancestry meta-analysis of pain intensity in 598,339 participants in the Million Veteran Program, which identified 125 independent genetic loci, 82 of which are novel. Pain intensity was genetically correlated with other pain phenotypes, level of substance use and substance use disorders, other psychiatric traits, education level, and cognitive traits. Integration of the GWAS findings with functional genomics data shows enrichment for putatively causal genes (n = 142) and proteins (n = 14) expressed in brain tissues, specifically in GABAergic neurons. Drug repurposing analysis identified anticonvulsants, beta-blockers, and calcium-channel blockers, among other drug groups, as having potential analgesic effects. Our results provide insights into key molecular contributors to the experience of pain and highlight attractive drug targets.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>Introduction</title><p id="P4">Pain is an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. Pain is often classified as either acute, which typically lasts less than 4 weeks, and chronic, lasting more than three months and potentially maladaptive<sup><xref rid="R2" ref-type="bibr">2</xref></sup>. An individual&#8217;s experience of pain is influenced by biological, psychological, and social factors<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup>.</p><p id="P5">In a national survey, 50.2 million US adults (20.5%) reported experiencing pain on most days or every day<sup><xref rid="R4" ref-type="bibr">4</xref></sup>, making pain the most common reason for seeking medical treatment<sup><xref rid="R5" ref-type="bibr">5</xref></sup> and resulting in total healthcare costs of 560 to 635 billion dollars in 2010<sup><xref rid="R6" ref-type="bibr">6</xref></sup>. Chronic pain is also associated with a poor quality of life<sup><xref rid="R7" ref-type="bibr">7</xref></sup>. In the late 1980's many medical and pain organizations adopted policies to increase patients&#8217; access to pain management, including opioids. These policies included efforts to ensure the adequate assessment of pain, which was designated as &#8220;the fifth vital sign&#8221;<sup><xref rid="R2" ref-type="bibr">2</xref></sup>. The resulting dramatic increase in prescriptions for opioid analgesics contributed to the opioid epidemic and a doubling of opioid-related deaths in the 1990s<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup>.</p><p id="P6">Success rates for treating chronic pain with currently available medications are estimated to be as low as 10%<sup><xref rid="R10" ref-type="bibr">10</xref></sup>. Opioids are not efficacious in managing chronic non-cancer pain<sup><xref rid="R11" ref-type="bibr">11</xref></sup> and their long-term use is associated with adverse effects such as addiction, sleep disturbance, opioid-induced hyperalgesia, endocrine changes, and cardiac and cognitive effects<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup>. Other medications used to treat chronic noncancer pain, such as non-steroidal anti-inflammatory medications and antiepileptic drugs, are effective for only some types of pain and may be associated with significant adverse effects<sup><xref rid="R14" ref-type="bibr">14</xref></sup>. Because non-pharmacologic interventions are not accessible to most patients with pain, safe and efficacious medications are needed to address this highly prevalent condition. Thus, novel therapeutic targets for chronic pain are needed to facilitate the discovery or repurposing of safe, effective analgesics.</p><p id="P7">Notably, drug development efforts informed by genetics can double the rate of success<sup><xref rid="R15" ref-type="bibr">15</xref>-<xref rid="R17" ref-type="bibr">17</xref></sup>. Although the heritability (h<sup>2</sup>) of individual differences in the susceptibility to develop chronic pain is estimated in twin and family studies to be 25&#8211;50%<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup>, the mechanisms that underlie it are poorly understood<sup><xref rid="R20" ref-type="bibr">20</xref></sup>. To date, genome-wide association studies (GWAS) of chronic pain in large samples, including the UK Biobank (UKBB) and 23andMe cohorts, have focused on specific bodily sites<sup><xref rid="R21" ref-type="bibr">21</xref>-<xref rid="R24" ref-type="bibr">24</xref></sup> or aspects of an individual&#8217;s sensitivity to experiencing and reporting pain<sup><xref rid="R25" ref-type="bibr">25</xref>-<xref rid="R28" ref-type="bibr">28</xref></sup>. Although in samples of 150,000 to nearly 500,000 individuals GWAS have identified genome-wide significant (GWS) loci for headache <sup><xref rid="R29" ref-type="bibr">29</xref></sup>, osteoarthritis <sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup>, low back pain <sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup>, knee pain <sup><xref rid="R21" ref-type="bibr">21</xref></sup>, neuropathic pain <sup><xref rid="R32" ref-type="bibr">32</xref></sup>, and multisite chronic pain<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup>, they have yielded few overlapping loci. This may be due to the different pain phenotypes employed, despite their having high genetic correlations among them<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R33" ref-type="bibr">33</xref></sup>.</p><p id="P8">There are also significant genetic correlations between pain phenotypes and psychiatric, substance use, cognitive, anthropometric, and circadian traits <sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R23" ref-type="bibr">23</xref>-<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup>. This shared genetic predisposition suggests that a common genetic susceptibility underlies a broad range of diverse chronic pain conditions<sup><xref rid="R34" ref-type="bibr">34</xref></sup> and common co-occurring conditions. For example, Mendelian randomization (MR) and latent causal variable analyses have shown positive causal effects of specific bodily site pain on depression<sup><xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R36" ref-type="bibr">36</xref></sup> and bi-directional casual associations between multisite chronic pain and major depressive disorder (MDD)<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup>.</p><p id="P9">Despite a growing literature on pain GWAS, most studies have been conducted in predominantly European ancestry cohorts recruited from non-clinical biobanks. However, biobanks linked to electronic health records (EHRs) with large, well-characterized, multi-ancestry samples are now available for use in identifying genetic risk factors and therapeutic targets for chronic pain<sup><xref rid="R37" ref-type="bibr">37</xref></sup>. The Million Veteran Program (MVP)<sup><xref rid="R38" ref-type="bibr">38</xref></sup>, an observational cohort study and mega-biobank implemented in the U.S. Department of Veterans Affairs (VA) health care system, includes data on routine pain screening. Pain ratings in the MVP use an 11-point ordinal Numeric Rating Scale (NRS), which has been a standard practice in VA primary care for more than a decade<sup><xref rid="R39" ref-type="bibr">39</xref></sup>. The NRS has been shown to be a consistent, valid measure of reported pain<sup><xref rid="R40" ref-type="bibr">40</xref>-<xref rid="R42" ref-type="bibr">42</xref></sup> and is particularly informative for a GWAS of pain, as over 50% of VA patients experience chronic pain<sup><xref rid="R43" ref-type="bibr">43</xref></sup>.</p><p id="P10">We conducted a cross-ancestry meta-analysis of the NRS in samples of African American (AA), European American (EA) and Hispanic American (HA) ancestries from the MVP (N = 598,339). Because of the frequency with which the NRS is administered to patients in the VA, for each individual we calculated the median annual score and then the median across years. Thus, although the NRS is a report of pain intensity experienced at a specific point in time, the median of medians provided a proxy for chronic pain. We also conducted a secondary analysis in a subsample of 566,959 individuals that excluded participants with a lifetime opioid use disorder (OUD) diagnosis to assess potential confounding by OUD.</p></sec><sec id="S2"><title>Methods</title><sec id="S3"><title>Overview of analyses</title><p id="P11">We conducted ancestry-specific GWASs of pain scores using an 11-point ordinal NRS in a) all AAs, EAs, and HAs with pain ratings from the MVP and b) a subset of these participants that excluded those with a lifetime OUD diagnosis, each followed by a cross-ancestry meta-analysis. Details on phenotyping are provided below. Downstream analyses are based principally on the GWAS of pain scores in the full sample, complemented by the estimated heritability and genetic correlations (<italic toggle="yes">r</italic><sub><italic toggle="yes">g</italic></sub><italic toggle="yes">s</italic>) for the sample exclusive of participants with OUD. An overview of the analyses is provided in <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 1</xref>.</p></sec><sec id="S4"><title>Million Veteran Program cohort</title><p id="P12">The MVP<sup><xref rid="R38" ref-type="bibr">38</xref></sup> is an EHR-based cohort comprising &gt;900,000 veterans recruited at 63 VA medical centers nationwide. All participants provided written informed consent, a blood sample for DNA extraction and genotyping, and approval to securely access their EHR for research purposes. The protocol and consent were approved by the Central Veterans Affairs Institutional Review Board (IRB) and all site-specific IRBs. All relevant guidelines for work with human participants were followed in the conduct of the study.</p></sec><sec id="S5"><title>Phenotype description</title><p id="P13">As early as 2000, the VA recommended using the NRS to routinely measure pain in clinical practice as a &#8220;fifth vital sign&#8221;<sup><xref rid="R44" ref-type="bibr">44</xref></sup>. Since that time, veterans have been asked to rate their pain severity in response to the question: &#8220;Are you in pain?&#8221; They then rated their current pain on a scale of 0-10 where &#8220;0 is no pain and 10 is the worst pain imaginable&#8221;. Participants had at least one inpatient or outpatient pain rating in the EHR. We included 598,339 individuals with 76,798,104 NRS scores (median number of scores = 109, IQR = 28 &#8211; 351) in the primary GWAS. To reduce the large number of pain observations, we calculated the median pain score by year for each participant and the median of the annual median pain scores. In a supplementary GWAS we excluded individuals with a documented ICD-9/10 diagnosis code for OUD in the EHR, yielding a total of 566,959 study participants. Demographic characteristics for the supplementary sample are presented in <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 1</xref>.</p></sec><sec id="S6"><title>Genotyping and imputation</title><p id="P14">DNA samples were genotyped on the Affymetrix Axiom Biobank Array (MVP Release 4). For genotyped SNPs, standard quality control (QC) and subsequent imputation were implemented. Full details about SNP and sample QC by the MVP Genomics Working Group are published<sup><xref rid="R45" ref-type="bibr">45</xref></sup>. Briefly, DNA samples were removed for sex mismatch, having seven or more relatives in MVP (kinship &gt; 0.08), excessive heterozygosity, or genotype call rate &lt; 98.5%. Variants were removed if they were monomorphic, had a high degree of missingness (call rate &lt; 0.8) or a Hardy&#8211;Weinberg equilibrium (HWE) threshold of <italic toggle="yes">P</italic> &lt; 1 &#215; 10<sup>6</sup> both in the entire sample using a principal-component analysis (PCA)-adjusted method and within one of the three major ancestral groups (AA, EA and HA).</p><p id="P15">Genotype phasing and imputation were performed using SHAPEIT4 (v.4.1.3)<sup><xref rid="R46" ref-type="bibr">46</xref></sup> and Minimac4 software<sup><xref rid="R47" ref-type="bibr">47</xref></sup>, respectively. Biallelic SNPs were imputed using the African Genome Resources reference panel by the Sanger Institute (comprising all samples from the 1000 Genomes Project phase 3, version 5 reference panel<sup><xref rid="R48" ref-type="bibr">48</xref></sup>, and 1,500 unrelated pan-African samples). Non-biallelic SNPs and indels were imputed in a secondary imputation step using the 1000 Genomes Project phase 3, version 5 reference panel<sup><xref rid="R48" ref-type="bibr">48</xref></sup>, with indels and complex variants from the second imputation merged into the African Genome Resources imputation.</p><p id="P16">We removed one individual from each pair of related individuals (kinship &gt; 0.08, <italic toggle="yes">N</italic> = 31,010) at random. The HARE method<sup><xref rid="R49" ref-type="bibr">49</xref></sup> was used to classify subjects into major ancestral groups (AA = 112,968, EA = 436,683, HA = 48,688) and QC of imputed variants was performed within each ancestral group. SNPs with imputation quality (INFO) score &lt; 0.7; minor allele frequency (MAF) in AAs &lt; 0.005, EAs &lt; 0.001, and HAs &lt; 0.01; a genotype call rate &lt; 0.95; or an HWE <italic toggle="yes">P</italic> &lt; 1 &#215; 10<sup>&#8722;6</sup> were excluded.</p></sec><sec id="S7"><title>Association analyses and risk locus definition</title><p id="P17">Genome-wide association testing was based on a linear regression model using PLINK (v.2.0)<sup><xref rid="R50" ref-type="bibr">50</xref></sup> and was adjusted for sex, age at enrollment, and the first 10 within-ancestry genetic principal components (PCs). Due to substantial differences in sample size across ancestral groups, meta-analyses were performed using a sample-size weighted method in METAL<sup><xref rid="R51" ref-type="bibr">51</xref></sup>. Variants with <italic toggle="yes">P</italic> &lt; 5 &#215; 10<sup>&#8722;8</sup> were considered genome-wide significant (GWS).</p><p id="P18">To identify risk loci and their lead variants, we performed LD clumping in FUMA<sup><xref rid="R52" ref-type="bibr">52</xref></sup> at a range of 3,000 kb, r<sup>2</sup> &gt; 0.1, and the respective ancestry 1000 Genomes reference panel<sup><xref rid="R48" ref-type="bibr">48</xref></sup>. Following clumping, genomic risk loci within 1 Mb of one another were incorporated into the same locus. We used GCTA COJO<sup><xref rid="R53" ref-type="bibr">53</xref></sup> to define independent variants by conditioning them on the most significant variant within the locus. After conditioning, significant variants (<italic toggle="yes">P</italic> &lt; 5 &#215; 10<sup>&#8722;8</sup>) were considered independently associated. We performed a sign test to compare the direction of SNP effects across individual ancestral datasets. Independent lead variants in EAs were examined in AAs and HAs and a binomial test used to evaluate the null hypothesis that 50% of variants have the same effect direction across ancestries. For lead SNPs in EAs that were absent in AAs and HAs, we considered proxy GWS SNPs (<italic toggle="yes">p</italic> &lt; 5&#215;10<sup>&#8722;8</sup>) in high LD with the EA lead variant (<italic toggle="yes">r</italic><sup>2</sup> &#8805;0.8).</p><p id="P19">To prioritize credible sets of variants driving our GWAS results, we used FINEMAP<sup><xref rid="R54" ref-type="bibr">54</xref></sup> to fine-map regions defined by LD clumps (r<sup>2</sup> &gt; 0.1). Because fine-mapping requires data from all markers in the region of interest<sup><xref rid="R55" ref-type="bibr">55</xref></sup>, we merged LD clumps that physically overlapped (within a 1-MB window of the lead variant) and excluded SNPs in the major histocompatibility complex (MHC) region due to its complexity. FINEMAP credible set reports the likelihood of causality using the marginal posterior probability (PP), which ranges from 0 to 1, with values closer to 1 being most likely causal.</p></sec><sec id="S8"><title>SNP-based heritability and functional enrichment</title><p id="P20">We used the linkage disequilibrium score (LDSC) regression<sup><xref rid="R56" ref-type="bibr">56</xref></sup> method to estimate the SNP-based heritability (h<sup>2</sup><sub>SNP</sub>) of pain intensity (in both the full and the supplementary samples) in AAs and EAs based on common SNPs in HapMap3<sup><xref rid="R57" ref-type="bibr">57</xref></sup>. Due to the small HA sample size, we could not calculate h<sup>2</sup><sub>SNP</sub> in this population. To ensure matching of population LD structure, pre-calculated LD scores for EAs were derived from the 1000 Genomes European reference population (version 3)<sup><xref rid="R49" ref-type="bibr">49</xref></sup> using LDSC<sup><xref rid="R56" ref-type="bibr">56</xref></sup>. In-sample LD scores for AAs were calculated from MVP AA genotype data using cov-LDSC<sup><xref rid="R58" ref-type="bibr">58</xref></sup>.</p><p id="P21">We used S-LDSC to partition the SNP heritability for pain intensity among EAs and explored the enrichment of the partitioned heritability by functional genomic categories<sup><xref rid="R59" ref-type="bibr">59</xref>,<xref rid="R60" ref-type="bibr">60</xref></sup> using three models: (a) a baseline-LD model that contains 75 overlapping annotations, including coding and regulatory regions of the genome and epigenomic features<sup><xref rid="R59" ref-type="bibr">59</xref></sup> (b) a specific tissue model that examines 10 overlapping cell-type groups derived from 220 cell-type-specific histone marks, including methylated histone H3 Lys4 (H3K4me1), trimethylated histone H3 Lys4 (H3K4me3), acetylated histones H3 Lys4 (H3K4ac) and H3K27ac<sup><xref rid="R59" ref-type="bibr">59</xref></sup> and (c) a multi-tissue model based on gene expression and chromatin datasets generated by GTEx<sup><xref rid="R61" ref-type="bibr">61</xref></sup> and the Roadmap Epigenomics Mapping Consortium<sup><xref rid="R62" ref-type="bibr">62</xref></sup>. For each model, we excluded multi-allelic and MHC region variants. Functional categories within each model were considered significantly enriched based on a Bonferroni-corrected <italic toggle="yes">P</italic> value.</p></sec><sec id="S9"><title>Gene-set functional characterization</title><p id="P22">We applied multi-marker analysis of genomic annotation (MAGMA) v.1.08<sup><xref rid="R63" ref-type="bibr">63</xref></sup> in FUMA (v1.3.6a)<sup><xref rid="R52" ref-type="bibr">52</xref></sup> to identify genes and gene sets associated with the findings from the pain intensity GWAS and meta-analysis. Using the default setting in MAGMA, we mapped GWS SNPs to 18,702 protein-coding genes according to their physical position in NCBI build 37. We also used chromatin interaction (Hi-C) coupled MAGMA (H-MAGMA)<sup><xref rid="R64" ref-type="bibr">64</xref></sup> to assign non-coding (intergenic and intronic) SNPs to genes based on their chromatin interactions. H-MAGMA uses six Hi-C datasets derived from fetal brain, adult brain (N = 3), induced pluripotent stem cell (iPSC)-derived neurons and iPSC-derived astrocytes<sup><xref rid="R65" ref-type="bibr">65</xref></sup>. We applied a Bonferroni correction (MAGMA, <italic toggle="yes">&#945;</italic> = 0.05/18,702; H-MAGMA, &#945; = 0.05/293157/6) to identify genes significantly associated with pain intensity, correcting for all genes tested in each analysis (see <xref rid="SD2" ref-type="supplementary-material">Supplementary Tables 15</xref> and <xref rid="SD2" ref-type="supplementary-material">21</xref> for full lists).</p><p id="P23">To determine the plausible tissue enrichment of mapped genes, we integrated our cross-ancestry and EA GWAS results with gene expression data from 54 tissues (GTEx v8) in FUMA<sup><xref rid="R52" ref-type="bibr">52</xref></sup>. Next, we used FUMA to curate gene sets and Gene Ontology terms (from the Molecular Signature Database v.7.0<sup><xref rid="R66" ref-type="bibr">66</xref></sup>). We corrected for gene size, density of variants, and LD pattern between genes in each tissue (Bonferroni-corrected <italic toggle="yes">&#945;</italic> = 0.05/54).</p><p id="P24">Enrichment for cell-type specific (CTS) transcriptomic profiles was performed in FUMA<sup><xref rid="R67" ref-type="bibr">67</xref></sup> using 13 human single-cell RNA-sequencing (sc-RNAseq) datasets derived from brain (see <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 14</xref> for a detailed list). FUMA estimates CTS transcriptomic enrichment from the sc-RNAseq in three ways: (1) per selected dataset, (2) within datasets using a conditionally independent analysis (based on stepwise conditional testing of <italic toggle="yes">P</italic> values for each cell type that passes Bonferroni correction within the same dataset), and (3) across datasets (testing for proportional significance across the results from step 2). Proportional significance (PS) reports the confidence level for observed cell type enrichment as low significance: &lt; 0.5, jointly significant: 0.5 &#8211; 0.8; and independently significant: &gt; 0.8. We considered CTS enrichments with conditional independent signals (<italic toggle="yes">P</italic> &lt; 0.05) and PS &gt; 0.5 to be driven by joint/independent genetic signals in our pain intensity GWAS results.</p></sec><sec id="S10"><title>Transcriptomic and proteomic regulation</title><p id="P25">To identify genes and proteins whose expression is associated with pain intensity, we integrated EA GWAS results with human brain transcriptomic (eQTL, N = 452; and sQTL, N = 452)<sup><xref rid="R68" ref-type="bibr">68</xref>,<xref rid="R69" ref-type="bibr">69</xref></sup> and proteomic (N = 722)<sup><xref rid="R62" ref-type="bibr">62</xref></sup> data. We also obtained pretrained models of gene expression from GTEx v.8 for five brain tissues significantly enriched in MAGMA analyses &#8211; cerebellum, cerebellar hemisphere, cortex, frontal cortex, and anterior cingulate cortex<sup><xref rid="R61" ref-type="bibr">61</xref>,<xref rid="R71" ref-type="bibr">71</xref></sup>. Human brain transcriptomic and proteomic data for dorsolateral prefrontal cortex were derived from the study by Wingo et al<sup><xref rid="R70" ref-type="bibr">70</xref></sup>. Transcriptome-wide association study (TWAS) and proteome-wide association study (PWAS) analyses were performed using the FUSION pipeline<sup><xref rid="R71" ref-type="bibr">71</xref></sup> with Bonferroni correction (&#945; = 0.05/N genes tested) to account for multiple testing.</p><p id="P26">We used the colocalization (coloc R package<sup><xref rid="R72" ref-type="bibr">72</xref></sup> in FUSION<sup><xref rid="R71" ref-type="bibr">71</xref></sup>) as our primary method to identify SNPs that mediate association with pain intensity through effects on gene and protein expression and a posterior colocalization probability (PP) of 80% to denote a shared causal signal. To test the robustness of the colocalized signals, we also performed summary-based Mendelian randomization (SMR) analyses<sup><xref rid="R73" ref-type="bibr">73</xref></sup>. We applied the HEIDI test<sup><xref rid="R73" ref-type="bibr">73</xref></sup> to filter out SMR signals (<italic toggle="yes">P</italic><sub>HEIDI</sub> &lt; 0.05) due to linkage disequilibrium between pain-associated variants and eQTLs/sQTLs. Human brain cis-eQTL and cis-sQTL summary data were obtained from Qi et al<sup><xref rid="R74" ref-type="bibr">74</xref></sup> and GTEx<sup><xref rid="R61" ref-type="bibr">61</xref></sup>. For genomic regions containing multiple genes with significant SMR associations, we selected the top-associated cis-eQTL. We used Bonferroni correction to correct for multiple testing (&#945; = 0.05/N genes tested).</p><p id="P27">To explore the enrichment of causal genes and proteins in the dorsal root ganglia (DRG), we accessed human and mouse RNA-seq data from 13 tissues (6 neural and 7 non-neural) from the DRG sensoryomics repository<sup><xref rid="R75" ref-type="bibr">75</xref></sup>. The data contain relative gene abundances in standardized transcripts per million mapped reads and have been normalized to allow comparison across genes. The proportions of gene expression in the CNS (neural proportion score) and DRG (DRG enrichment score) in the context of profiled tissues were calculated, as described in Ray et al<sup><xref rid="R75" ref-type="bibr">75</xref></sup>. Scores ranging from 0 to 1 were used to denote the strength of tissue enrichment.</p></sec><sec id="S11"><title>Drug repurposing</title><p id="P28">We examined the drug repurposing status of genes in EAs (N = 156) with high causal probability from fine mapping and transcriptomic and proteomic analyses, using the Druggable Genome database<sup><xref rid="R76" ref-type="bibr">76</xref></sup>. For completeness, we also included the significantly associated genes mapped to GWS variants and MAGMA results in AAs (N = 7) and HAs (N = 2). The Druggable Genome database contains 4,479 coding gene sets with the potential to be modulated by a drug-like small molecule based on their nucleotide sequence and structural similarity to targets of existing drugs<sup><xref rid="R76" ref-type="bibr">76</xref></sup>. This druggable genome was divided into three tiers. Tier 1 (N = 1,427) contains targets of licensed small molecules and biotherapeutic drugs (curated from the ChEMBL database<sup><xref rid="R77" ref-type="bibr">77</xref></sup>) and drugs in clinical development. Tier 2 (N = 682) includes targets with verified bioactive drug-like small molecule binding partners and &gt; 50% identity with approved drug targets based on their nucleotide sequence. Tier 3 (N = 2,370) comprises targets or secreted proteins with more distant similarity with an approved drug and members of active protein complexes not included in Tiers 1 and 2. All causal genes and those reported in any of the three tiers of the Druggable Genome were also examined for interaction with prescription drug targets in clinical development using the Drug-Gene Interaction database (DGIdb)<sup><xref rid="R78" ref-type="bibr">78</xref></sup>, which compiles clinical trial information from the FDA, PharmGKB, Therapeutic Target Database, and DrugBank databases, among others. We categorized each prescription drug identified using the Anatomical Therapeutic Chemical classification system, retrieved from the Kyoto Encyclopedia of Genes and Genomics (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.genome.jp/kegg/drug/" ext-link-type="uri">https://www.genome.jp/kegg/drug/</ext-link>).</p></sec><sec id="S12"><title>Genetic correlation</title><p id="P29">We used LDSC<sup><xref rid="R56" ref-type="bibr">56</xref></sup> to calculate the <italic toggle="yes">r</italic><sub>g</sub> of pain intensity with (a) 89 other published pain, substance use, medication use, psychiatric, and anthropometric traits from EA datasets selected using prior epidemiological evidence and (b) 12 psychiatric, substance use, and anthropometric traits based on available AA GWAS summary data (see <xref rid="SD2" ref-type="supplementary-material">Supplementary Tables 24</xref> and <xref rid="SD2" ref-type="supplementary-material">26</xref> for detailed lists). In EAs, all traits were tested using pre-computed LD scores for HapMap3<sup><xref rid="R57" ref-type="bibr">57</xref></sup>, while in AAs, LD scores derived using cov-LDSC<sup><xref rid="R58" ref-type="bibr">58</xref></sup> from MVP AA genotype data were used. In a hypothesis-neutral manner, we also calculated <italic toggle="yes">r</italic><sub>g</sub>s of pain intensity with 1344 published and unpublished traits from the UKBB using the Complex Trait Virtual Lab (CTG-VL) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://genoma.io/" ext-link-type="uri">https://genoma.io/</ext-link>). CTG-VL is a free open-source platform that incorporates publicly available GWAS data that allow for the calculation of <italic toggle="yes">r</italic><sub>g</sub> for complex traits using LDSC<sup><xref rid="R79" ref-type="bibr">79</xref></sup>. Each set of <italic toggle="yes">r</italic><sub>g</sub> analyses was Bonferroni corrected to control for multiple comparisons (&#945; = 0.05/number of traits tested).</p><p id="P30">We also estimated the cross-ancestry <italic toggle="yes">r</italic><sub>g</sub>s for pain intensity between AAs, EAs and HAs using Popcorn<sup><xref rid="R80" ref-type="bibr">80</xref></sup>, a computational method that determines the correlation of causal-variant effect sizes at SNPs common across population groups using GWAS summary-level data and LD information. Ancestry-specific LD scores were derived from the 1000 Genomes reference population<sup><xref rid="R48" ref-type="bibr">48</xref></sup>.</p></sec><sec id="S13"><title>Polygenic risk score-based phenome-wide association studies</title><p id="P31">We calculated polygenic risk scores (PRS) for pain intensity and performed a PheWAS analysis in two samples &#8211; the Yale-Penn sample and the Penn Medicine Biobank (PMBB). The Yale-Penn sample<sup><xref rid="R81" ref-type="bibr">81</xref></sup> was deeply phenotyped using the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA), a comprehensive psychiatric instrument that assesses physical, psychosocial, and psychiatric aspects of SUDs and comorbid psychiatric traits <sup><xref rid="R82" ref-type="bibr">82</xref>,<xref rid="R83" ref-type="bibr">83</xref></sup>. As described in detail previously <sup><xref rid="R81" ref-type="bibr">81</xref></sup>, genotyping was performed using the Illumina HumanOmni1-Quad microarray, the Illumina HumanCoreExome array, or the Illumina Multi-Ethnic Global array, followed by imputation using Minimac3<sup><xref rid="R84" ref-type="bibr">84</xref></sup> and the 1000 Genomes Project phase3 reference panel<sup><xref rid="R48" ref-type="bibr">48</xref></sup> implemented on the Michigan imputation server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://imputationserver.sph.umich.edu/" ext-link-type="uri">https://imputationserver.sph.umich.edu</ext-link>). SNPs with imputation quality (INFO) score&lt;0.7, MAF &lt; 0.01, missingness &gt; 0.01, or an allele frequency difference between batches &gt; 0.04; and individuals with genotype call rate &lt; 0.95, or related individuals with pi-hat &gt; 0.25 were excluded. PCs were used to determine genetic ancestry based on the 1000 Genomes Project phase3<sup><xref rid="R48" ref-type="bibr">48</xref></sup>. The resulting dataset included 4,922 AAs and 5,709 EAs.</p><p id="P32">The PMBB<sup><xref rid="R85" ref-type="bibr">85</xref></sup> is linked to EHR phenotypes. PMBB samples were genotyped with the GSA genotyping array. Genotype phasing was done using EAGLE<sup><xref rid="R84" ref-type="bibr">84</xref></sup> and imputation was performed using Minimac3<sup><xref rid="R84" ref-type="bibr">84</xref></sup> on the TOPMed Imputation server<sup><xref rid="R47" ref-type="bibr">47</xref></sup>. Following QC (INFO&lt; 0.3, missingness &gt;0.95, MAF &gt; 0.5, sample call rate &gt; 0.9), PLINK 1.90 was used to identify and remove related individuals based on identity by descent (Pi-hat &gt; 0.25). To estimate genetic ancestry, PCs were calculated using SNPs common to the PMBB and the 1000 Genomes Project phase3<sup><xref rid="R48" ref-type="bibr">48</xref></sup> and the smartpca module of the Eigensoft package (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/DReichLab/EIG" ext-link-type="uri">https://github.com/DReichLab/EIG</ext-link>). Participants were assigned to an ancestral group based on the distance of 10 PCs from the 1000 Genomes reference populations. The resulting dataset included 10,383 AAs and 29,355 EAs.</p><p id="P33">PRSs for pain intensity were calculated in the Yale-Penn and the PMBB datasets using PRS-Continuous shrinkage software (PRS-CS)<sup><xref rid="R86" ref-type="bibr">86</xref></sup>, with the default setting used to estimate the shrinkage parameters and the random seed fixed to 1 for reproducibility. To identify associations between the pain intensity PRSs and phenotypes, we performed a PheWAS in each dataset by fitting logistic regression models for binary traits and linear regression models for continuous traits. Analyses were conducted using the PheWAS v0.12 R package<sup><xref rid="R87" ref-type="bibr">87</xref></sup> with adjustment for sex, age at enrollment (in PMBB) or at interview (in Yale-Penn) and the first 10 PCs within each genetic ancestry. We Bonferroni corrected each ancestry-specific analysis (Yale-Penn EAs and AAs: <italic toggle="yes">P</italic> &lt; 8.10 &#215; 10<sup>&#8722;5</sup>, PMBB EAs and AAs: <italic toggle="yes">P</italic> &lt; 3.68 &#215; 10<sup>&#8722;5</sup>).</p></sec><sec id="S14"><title>Mendelian Randomization</title><p id="P34">We used two-sample Mendelian randomization<sup><xref rid="R88" ref-type="bibr">88</xref></sup> to evaluate causal associations between 16 genetically correlated traits and pain intensity among EAs only because the two other population groups provided inadequate statistical power for the analysis. We inferred causality bidirectionally using three methods: weighted median, inverse-variance weighted (IVW) and MR-Egger, followed by a pleiotropy test using the MR Egger intercept. Instrumental variants were associated with the exposure at <italic toggle="yes">P</italic> &lt; 1 &#215; 10<sup>&#8722;5</sup> and a clumping threshold of <italic toggle="yes">r</italic><sup>2</sup> = 0.01. Potential causal effects were those for which at least two MR tests were significant after multiple correction (<italic toggle="yes">P</italic> = 3.13 &#215; 10<sup>&#8722;3</sup>, 0.05/16) and did not violate the assumption of horizontal pleiotropy (MR-Egger intercept <italic toggle="yes">P</italic> &gt; 0.05).</p></sec></sec><sec id="S15"><title>Results</title><sec id="S16"><title>Description of the sample</title><p id="P35">The study sample comprised 598,339 individuals (AA = 112,968, EA = 436,683, HA = 48,688), of whom 91.2% were male (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 1</xref>). The supplementary analyses from which individuals with a lifetime OUD diagnosis were excluded were reduced by 5% across population groups (AA = 104,050, EA = 415,740, HA = 46,169) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 1</xref>). The median ages were 61.4 (s.d = 14.0) and 61.7 (s.d = 14.1) in the full and supplementary samples, respectively. About half of individuals in both the full sample (51.2%) and the supplementary sample (52.7%) reported a median NRS of 0, i.e., no pain. Mild (NRS 1-3), moderate (NRS 4-6) and severe pain (NRS 7-10) were reported by 24.4%, 19.2%, and 4.5%, respectively in the full sample, and 24.6%, 18.2%, and 4.0%, respectively in the supplementary sample.</p></sec><sec id="S17"><title>Identification of pain intensity risk loci</title><p id="P36">In our cross-ancestry meta-analysis of AA, EA, and HA samples, we identified 4,416 GWS variants represented by 158 LD-clumped index variants (r<sup>2</sup> &gt; 0.1) (<xref rid="F1" ref-type="fig">Figure 1</xref>). Analyses conditioned on the lead SNP left 125 independent association signals (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 2</xref>), 42 of which have previously been reported as pain-related loci<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> and 82 of which are novel (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 2</xref>). Eight independent variants are exonic, 84 reside within a gene transcript, and 33 are intergenic. Of the 8 exonic variants, 2 have likely damaging (PolyPhen &gt; 0.5, CADD &gt; 15) effects (<italic toggle="yes">SLC39A8</italic>-rs13107325 and <italic toggle="yes">WSCD2</italic>-rs3764002) and 5 are potentially deleterious (CADD &gt; 15; <italic toggle="yes">ANAPC4</italic>-rs34811474, <italic toggle="yes">MIER</italic>-rs2034244, <italic toggle="yes">NUCB2</italic>-rs757081, <italic toggle="yes">AKAP10</italic>-rs203462 and <italic toggle="yes">APOE</italic>-rs429358) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 2</xref>). The GWAS in EAs yielded 103 LD clumps (r<sup>2</sup> &gt; 0.1) across 86 independent loci (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 2</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 3</xref>). Of these, 15 were not GWS in the cross-ancestry meta-analysis (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 3</xref>). We also identified 2 GWS variants in 1 locus (nearest gene <italic toggle="yes">PPARD</italic>; chr 6) in AAs, and 15 GWS variants in 2 loci (nearest genes <italic toggle="yes">RNU6-461P</italic>; chr 3 and <italic toggle="yes">RNU6-741P</italic>; chr 15) in HAs (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 4</xref>).</p><p id="P37">We used a sign test to examine the 86 independent EA index variants in AAs and HAs, of which 57 and 74, respectively, were directly analyzed or had proxy SNPs in these populations (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 5</xref>). Most variants had the same direction of effect in both populations (<italic toggle="yes">N</italic><sub>SNPs</sub> AAs = 41, HAs = 61; sign test AAs <italic toggle="yes">P</italic> = .0013, HAs <italic toggle="yes">P</italic> = 1.39 &#215; 10<sup>&#8722;8</sup>). Only 15 variants (<italic toggle="yes">N</italic><sub>SNPs</sub> AAs = 2, HAs = 13) were nominally associated (<italic toggle="yes">P</italic> &lt; 0.05) and none survived multiple test correction (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 5</xref>). The cross-ancestry genetic-effect correlation (&#961;<sub>pe</sub>) was 0.71 (SE = 0.13, <italic toggle="yes">P</italic> = 2.12 &#215; 10<sup>&#8722;2</sup>) between EAs and AAs and 0.74 (SE = 0.08, <italic toggle="yes">P</italic> = 6.81 &#215; 10<sup>&#8722;4</sup>) between EAs and HAs. The cross-ancestry heritability estimates between AAs and HAs were too low to calculate &#961;<sub>pe</sub> between those ancestries.</p><p id="P38">In the supplementary analysis that excluded participants with a lifetime OUD diagnosis, we identified 3,400 SNPs in 101 LD-independent risk loci (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 6</xref>). Of these, 87 were GWS, 13 were <italic toggle="yes">p</italic> &lt; 10<sup>&#8722;6</sup> in the primary GWAS, and 18 were ancestry specific (17 in EAs and 1 in AAs) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Tables 7</xref> &amp; <xref rid="SD2" ref-type="supplementary-material">8</xref>).</p></sec><sec id="S18"><title>Single-nucleotide polymorphism heritability and enrichment</title><p id="P39">The proportion of variation in pain intensity explained by common genetic variants (h<sup>2</sup><sub>SNP</sub>) was similar both for the full samples (AAs: 0.06 &#177; 0.009 and EAs: 0.08 &#177; 0.003) and the supplementary samples without OUD (AAs: 0.07 &#177; 0.009 and EAs: 0.08 &#177; 0.003) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 9</xref>).</p><p id="P40">Partitioning the SNP heritability for pain intensity revealed significant tissue-group enrichment in central nervous system (CNS) (<italic toggle="yes">P</italic> = 1.47 &#215; 10<sup>&#8722;12</sup>), adrenal (<italic toggle="yes">P</italic> = 8.97 &#215; 10<sup>&#8722;5</sup>), liver (<italic toggle="yes">P</italic> = 3.15 &#215; 10<sup>&#8722;4</sup>), skeletal (<italic toggle="yes">P</italic> = 8.50 &#215; 10<sup>&#8722;4</sup>) and cardiovascular (<italic toggle="yes">P</italic> = .001) tissues (<xref rid="F2" ref-type="fig">Figure 2A</xref> &amp; <xref rid="F2" ref-type="fig">B</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 10</xref>). In gene expression datasets derived from multiple tissues, we observed predominant h<sup>2</sup><sub>SNP</sub> effects in brain (<italic toggle="yes">P</italic> = 2.87 &#215; 10<sup>&#8722;5</sup>), including hippocampus (<italic toggle="yes">P</italic> = 1.00 &#215; 10<sup>&#8722;4</sup>) and limbic system (<italic toggle="yes">P</italic> = 1.15 &#215; 10<sup>&#8722;4</sup>) (<xref rid="F2" ref-type="fig">Figures 2C</xref> &amp; <xref rid="F2" ref-type="fig">D</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 11</xref>). SNP-based heritability in histone modification data also showed robust enhancer (H3K27ac and H3K4me1) and active promoter (H3K4me3 and H3K9ac) enrichments in brain tissues, including the dorsolateral prefrontal cortex (<italic toggle="yes">P</italic> &lt; 1.32 &#215; 10<sup>&#8722;4</sup>), inferior temporal lobe (<italic toggle="yes">P</italic> &lt; 3.09 &#215; 10<sup>&#8722;4</sup>), angular gyrus (<italic toggle="yes">P</italic> = 8.42 &#215; 10<sup>&#8722;5</sup>), and anterior caudate (<italic toggle="yes">P</italic> = 1.12 &#215; 10<sup>&#8722;4</sup>) (<xref rid="F2" ref-type="fig">Figure 2E</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 12</xref>). Similar results were obtained for the partitioned heritability analysis of the supplementary GWAS (<xref rid="SD2" ref-type="supplementary-material">Supplementary Tables 11</xref> &amp; <xref rid="SD2" ref-type="supplementary-material">12</xref>), though it also included significant expression effects in the cortex and cerebellum.</p><p id="P41">Although the SNP-based heritability and enrichment for the full and supplementary GWASs were similar, because the full sample yielded more risk loci, we based all downstream analyses (except genetic correlation [<italic toggle="yes">r</italic><sub>g</sub>] analyses) on the GWAS results from that sample.</p></sec><sec id="S19"><title>Gene-set enrichment in tissue and cell types</title><p id="P42">To clarify the potential transcriptomic mechanism of each GWS pain locus, we mapped GWAS variants to genes via expression quantitative trait locus (eQTL) association in GTEx<sup><xref rid="R61" ref-type="bibr">61</xref></sup> and assessed the tissue enrichment of mapped genes in FUMA<sup><xref rid="R52" ref-type="bibr">52</xref></sup>. After correcting for multiple testing (<italic toggle="yes">P</italic> = 9.25 &#215; 10<sup>&#8722;4</sup>) in the cross-ancestry and EA-specific GWASs, we uncovered significant transcriptomic enrichment only in brain tissues (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 3</xref>). Consistent with previous findings of brain tissue enrichment across different pain phenotypes in EAs<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup>, both our EA and cross-ancestry analyses showed notable enrichment in the cerebellum (cross-ancestry, <italic toggle="yes">P</italic> = 2.48 &#215; 10<sup>&#8722;7</sup>; EA, <italic toggle="yes">P</italic> = 2.90 &#215; 10<sup>&#8722;6</sup>), cerebellar hemisphere (cross-ancestry, <italic toggle="yes">P</italic> = 4 &#215; 10<sup>&#8722;7</sup>; EA, <italic toggle="yes">P</italic> = 6.23 &#215; 10<sup>&#8722;6</sup>), cortex (cross-ancestry, <italic toggle="yes">P</italic> = 2.79 &#215; 10<sup>&#8722;6</sup>; EA, <italic toggle="yes">P</italic> = 3 &#215; 10<sup>&#8722;4</sup>), and frontal cortex (cross-ancestry, <italic toggle="yes">P</italic> = 2.82 &#215; 10<sup>&#8722;6</sup>; EA, <italic toggle="yes">P</italic> = 4.17 &#215; 10<sup>&#8722;4</sup>) (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 3</xref>). Among AAs there were no significantly enriched tissues (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 13</xref>).</p><p id="P43">To investigate enrichment at the level of the cell type in the EA GWAS results, we conducted FUMA cell-type specific analysis<sup><xref rid="R67" ref-type="bibr">67</xref></sup> in a collection of cell types in 13 human brain sc-RNAseq datasets. After adjusting for possible confounding due to correlated expression within datasets using a stepwise conditional analysis, we detected jointly significant cell-type enrichments (proportional significance, PS &gt; 0.5) for GABAergic neurons largely in the human adult mid-brain (<italic toggle="yes">P</italic> = 0.003 <italic toggle="yes">&#946;</italic> = 0.206, s.e. = 0.075, PS 0.56) and to a lesser extent in the prefrontal cortex (<italic toggle="yes">P</italic> = 0.044, <italic toggle="yes">&#946;</italic> = 0.045, s.e. = 0.016, PS 0.39) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 14</xref>).</p></sec><sec id="S20"><title>Prioritization of candidate genes</title><p id="P44">To facilitate the biological interpretation and identification of druggable targets, we used a combination of MAGMA and fine-mapping, transcriptomic, proteomic, and chromatin interaction models to prioritize high-confidence variants and genes that most likely drive GWAS associations. Assigning SNPs to genes using physical proximity, MAGMA gene-based analyses<sup><xref rid="R63" ref-type="bibr">63</xref></sup> identified 6 GWS genes in AAs, 203 in EAs, and 125 in the cross-ancestry results (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 4</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 15</xref>), but none in HAs. MAGMA gene-set analysis<sup><xref rid="R63" ref-type="bibr">63</xref></sup> using cross-ancestry GWAS results identified significantly enriched biological processes in catecholamine uptake (GO:0051944; Bonferroni <italic toggle="yes">P</italic> = 0.019) and startle response (GO:0001964; Bonferroni <italic toggle="yes">P</italic> = 0.024). Negative regulation of synaptic transmission (GO:0050805; Bonferroni <italic toggle="yes">P</italic> = 0.016) was related to pain intensity in EAs (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 16</xref>).</p><p id="P45">For consistency with available reference data, we based the fine mapping procedure on EA GWAS results using 78 genomic regions (spanning 103 index variants) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 17</xref>) defined by the maximum physical distance between the LD block of independent lead SNPs (<xref rid="S2" ref-type="sec">Methods</xref>). Functional genomic prediction models used the full EA GWAS results (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 1</xref>).</p><p id="P46">We fine-mapped the 78 regions using the Bayesian method implemented in FINEMAP<sup><xref rid="R54" ref-type="bibr">54</xref></sup> (<xref rid="S2" ref-type="sec">Methods</xref>). For each region with independent causal signals (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 17</xref>), credible sets of variants (PP &gt; 0.5) were constructed to capture 95% of the regional posterior probability (k &#8804; 5, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 18</xref>). Of these regions, 4 harbored 1 SNP (potentially indicating the causal variant), 20 regions 2 SNPs and 44 regions 3 or more SNPs (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 18</xref>). In total, FINEMAP prioritized 76 unique credible variants (N = 108, <xref rid="F3" ref-type="fig">Figure 3A</xref>), including 26 independent lead SNPs and 18 novel pain loci (<xref rid="F3" ref-type="fig">Figure 3B</xref>). Most (50/76) of the credible variants map to protein-coding genes and are mostly eQTLs (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 18</xref>), and five harbor missense variants, of which three (<italic toggle="yes">ANAPC4, APOE,</italic> and <italic toggle="yes">SLC39A8</italic>) are known pain loci<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup> and two (<italic toggle="yes">RYR2</italic> and <italic toggle="yes">AKAP10</italic>) are novel (<xref rid="F3" ref-type="fig">Figure 3B</xref>). This small proportion of missense variants and high eQTL enrichment are consistent with an increased probability that the credible variants influence liability to pain intensity through gene expression modulation.</p><p id="P47">We performed TWAS and PWAS analyses to determine whether risk variants exert their effects via gene and/or protein expression. After correction for multiple testing, 196 unique genes (TWAS eQTL &#8211; 294, TWAS sQTL &#8211; 67 and PWAS &#8211; 32) were associated with pain intensity (<xref rid="SD2" ref-type="supplementary-material">Supplementary Tables 19</xref> &amp; <xref rid="SD2" ref-type="supplementary-material">20</xref>). Of these, 69 represent novel associations (based on a window from the index GWAS locus &gt; 1 MB). PWAS showed significant associations in the dorsolateral prefrontal cortex (dlPFC) that overlapped for 22 unique genes across multiple brain tissues in the TWAS (eQTL &#8211; 16, sQTL &#8211; 8) (<xref rid="F3" ref-type="fig">Figure 3C</xref>).</p><p id="P48">Chromatin interaction mapping using Hi-C data in adult and fetal brain identified 512 unique significantly interacting genes (<italic toggle="yes">P</italic> = 2.84 &#215; 10<sup>&#8722;8</sup>) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 21</xref>), of which 60 are associated with all six chromatin annotations (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 5</xref>) and 20 overlap with TWAS and/or PWAS findings, including <italic toggle="yes">DPYSL5, KHK, MAPRE3, MST1R, NEK4, GNL3, GRK4, UHRF1BP1</italic> and <italic toggle="yes">VKORC1</italic> (<xref rid="F3" ref-type="fig">Figure 3C</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Tables 19</xref>, <xref rid="SD2" ref-type="supplementary-material">20</xref> &amp; <xref rid="SD2" ref-type="supplementary-material">21</xref>).</p><p id="P49">Based on concordant evidence from colocalization analyses in TWAS and PWAS (COLOC PP4 &gt; 0.80), 104 unique genes (TWAS eQTL &#8211; 139, TWAS sQTL &#8211; 20 and PWAS &#8211; 14) were putatively causal for pain intensity (<xref rid="SD2" ref-type="supplementary-material">Supplementary Tables 19</xref> &amp; <xref rid="SD2" ref-type="supplementary-material">20</xref>), of which 10 (including <italic toggle="yes">DPYSL5, GRK4, KHK</italic> and <italic toggle="yes">MST1R</italic>) were validated by SMR analysis (<italic toggle="yes">P</italic><sub>HEIDI</sub> &gt; 0.05) (<xref rid="F3" ref-type="fig">Figure 3D</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 22</xref>). Among the 104 genes, 6 (<italic toggle="yes">CHMP1A</italic>, <italic toggle="yes">GRIA1, GRK4, MST1R, STMN3</italic> and <italic toggle="yes">TRAF3</italic>) captured 50% or more of the FINEMAP posterior probability (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 18</xref>). Notably, the <italic toggle="yes">MST1R</italic> intronic locus (rs9815930), which is in a credible set that harbors four other variants in high LD with the novel index variant rs2247036 (nearest gene &#8211; <italic toggle="yes">TRAIP</italic>) (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 6</xref>), displayed the most robust causal effects from COLOC and SMR in more than one brain tissue (<xref rid="F3" ref-type="fig">Figure 3D</xref>).</p><p id="P50">We also explored enrichment of causal genes and proteins in the dorsal root ganglia (DRG), which are important for transduction of nociceptive signals from the periphery to the CNS. None of the causal genes or proteins (N = 104) were enriched in human or mouse DRG (DRG enrichment score &gt; 0.5) (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 7A</xref>). Supporting results from TWAS and PWAS, 63 unique genes (human &#8211; 38 and mouse &#8211; 49) were primarily enriched in the CNS, of which 22 (including <italic toggle="yes">GRK4, GRIA1, MAPRE3, NEK4, STMN3</italic> and <italic toggle="yes">TRAF3</italic>) showed common enrichment patterns across species (Supplementary Figure 7B).</p><p id="P51">Integrating FINEMAP, colocalization and SMR prioritized 156 high-confidence genes underlying the pain intensity GWAS association, of which 5 are exonic and missense (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 23</xref>), and 151 exert their effect via gene or protein expression.</p></sec><sec id="S21"><title>Phenotypic correlates of pain intensity</title><p id="P52">As expected, the strongest positive genetic correlations of pain intensity were with other pain phenotypes (e.g., multisite chronic pain <italic toggle="yes">r</italic><sub><italic toggle="yes">g</italic></sub>=0.789, osteoarthritis <italic toggle="yes">r</italic><sub><italic toggle="yes">g</italic></sub>=0.710, neck/shoulder pain <italic toggle="yes">r</italic><sub><italic toggle="yes">g</italic></sub>=0.669, back pain <italic toggle="yes">r</italic><sub><italic toggle="yes">g</italic></sub>=0.697, hip pain <italic toggle="yes">r</italic><sub><italic toggle="yes">g</italic></sub>=0.729, knee pain <italic toggle="yes">r</italic><sub><italic toggle="yes">g</italic></sub>=0.637; <xref rid="F4" ref-type="fig">Figure 4A</xref>). Of 72 medical, anthropometric, or psychiatric traits associated epidemiologically with pain severity and mortality, 56 were significantly genetically correlated with pain intensity in EAs (Bonferroni <italic toggle="yes">P</italic> &lt; 5.62 &#215; 10<sup>&#8722;4</sup>) (<xref rid="F4" ref-type="fig">Figure 4A</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 24</xref>).</p><p id="P53">Notably, the liability to pain intensity was significantly positively genetically correlated with neuroticism, depression, insomnia, a variety of smoking-related measures, cannabis use disorder (CUD), alcohol dependence, OUD, and overweight and obesity (<xref rid="F4" ref-type="fig">Figure 4A</xref>). As in prior studies<sup><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R89" ref-type="bibr">89</xref></sup>, pain intensity was significantly negatively correlated with educational attainment, cognitive performance, intelligence, and age of smoking initiation (<xref rid="F4" ref-type="fig">Figure 4A</xref>). Relevant to drug repurposing, pain intensity was also positively correlated with the use of a variety of analgesic and anti-inflammatory drugs (<xref rid="F4" ref-type="fig">Figure 4A</xref>). We also found significant <italic toggle="yes">r</italic><sub>g</sub>s with pain intensity for several medical conditions and health outcomes in the UKBB (including genitourinary disease, chronic bronchitis, angina, etc., Bonferroni <italic toggle="yes">P</italic> &lt; 3.72 &#215; 10<sup>&#8722;5</sup>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 25</xref>). In AAs, pain intensity was positively genetically correlated with PTSD-related features (e.g., re-experiencing, hyperarousal) and nominally associated (<italic toggle="yes">p</italic> &lt; 0.05) with substance use traits (e.g., maximum alcohol intake and smoking trajectory, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 26</xref>).</p><p id="P54">In the Yale-Penn sample, we calculated PRS for 4,922 AAs and 5,709 EAs. Among AAs, none of the associations survived Bonferroni correction, likely due to the smaller discovery sample than for EAs (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 8</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 27</xref>). In EAs, PheWAS identified 147 phenotypes, including 107 in the substance-related domain (40 opioid-related, 30 cocaine-related, 20 tobacco-related, 12 alcohol-related, and 6 cannabis-related) and 39 in other domains (9 medical, 18 psychiatric [9 PTSD, 5 ADHD, 2 conduct disorder, and 2 antisocial], 7 early childhood environmental, and 5 demographic phenotypes) that were significantly associated with the pain PRS (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 9</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 27</xref>). The most significant findings were a negative association of the pain severity PRS with educational attainment (<italic toggle="yes">P</italic> = 2.39 &#215; 10<sup>&#8722;26</sup>) and a positive association with the Fagerstr&#246;m Test for Nicotine Dependence (<italic toggle="yes">P</italic> = 4.71 &#215; 10<sup>&#8722;25</sup>). Opioid dependence was also positively associated with the pain PRS (<italic toggle="yes">P</italic> = 3.87 &#215; 10<sup>&#8722;12</sup>), and remained significant when using a PRS based on the supplementary GWAS that excluded individuals with an OUD diagnosis (OR = 1.27, <italic toggle="yes">P</italic> = 1.35 &#215; 10<sup>&#8722;6</sup>).</p><p id="P55">In PMBB, we calculated PRS for 10,383 AAs and 29,355 EAs. In AAs, no association with the pain PRS survived Bonferroni correction (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 10</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 28</xref>). In EAs, the pain severity PRS was associated with 63 phenotypes, including 7 pain phenotypes and 6 psychiatric disorders (i.e., substance-, depression-, and anxiety-related traits). Other phenotypic categories with associations with the pain severity PRS were circulatory system (n=11), infectious diseases (n=4), endocrine/metabolic (n=8), genitourinary (n=2), musculoskeletal (n=3), and neoplasms (n=4). The most significant findings were positive correlations with obesity (<italic toggle="yes">P</italic> = 1.97 &#215; 10<sup>&#8722;45</sup>) and tobacco use disorder (<italic toggle="yes">P</italic> = 1.55 &#215; 10<sup>&#8722;24</sup>) and a negative association with benign neoplasm of skin (<italic toggle="yes">P</italic> = 2.67 &#215; 10<sup>&#8722;26</sup>) (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 11</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 28</xref>).</p><p id="P56">Two-sample MR between genetically correlated traits (N = 16) and pain intensity yielded 10 traits with evidence of causal association, 8 of which were bidirectional (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 29</xref>). Genetically predicted higher opioid use (N02A), depressed affect subcluster, major depressive disorder, neuroticism, use of drugs to treat peptic ulcer, and smoking cessation (coded as current smoking) had a significant positive bidirectional causal effect with pain intensity, whereas educational attainment and cognitive performance had a significant negative bidirectional causal effect (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 29</xref>). Further, increased risk of pain intensity positively predicted smoking initiation and cigarettes per day.</p></sec><sec id="S22"><title>Genetically inferred drug repurposing</title><p id="P57">Of the 156 genes in EAs with evidence supporting causality from fine-mapping and functional genomic prediction, 20 were present in the druggable genome database<sup><xref rid="R76" ref-type="bibr">76</xref></sup> (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 30</xref>). Of these druggable candidate genes, 11 (including <italic toggle="yes">GRIA1, GRK4</italic> and <italic toggle="yes">MST1R</italic>) are tier-1 candidates, which includes targets of licensed drugs and drugs in clinical trial, 4 genes (e.g., <italic toggle="yes">NEK4</italic> and <italic toggle="yes">RYR2</italic>) are in tier 2, and 4 are in tier 3 (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 30</xref>). Within tier 1, drugs that interact with <italic toggle="yes">GRK4</italic> (a credible pain gene locus in moderate LD with the novel index variant <italic toggle="yes">NOP14</italic>*rs71597204 &#8211; <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 12</xref>) are beta-blockers (atenolol and metoprolol) and a calcium-channel blocking agent (verapamil) (<xref rid="F4" ref-type="fig">Figure 4B</xref>), which have analgesic effects in osteoarthritis<sup><xref rid="R90" ref-type="bibr">90</xref>,<xref rid="R91" ref-type="bibr">91</xref></sup> and migraine<sup><xref rid="R92" ref-type="bibr">92</xref></sup>. Another tier-1 candidate gene &#8211; <italic toggle="yes">GRIA1</italic> &#8211; is targeted by anesthetics (sevoflurane, isoflurane, desflurane), antiepileptics (topiramate, perampanel), analgesics (methoxyflurane), psychoanaleptics (piracetam, aniracetam), and a diuretic (cyclothiazide) (<xref rid="F4" ref-type="fig">Figure 4B</xref>). Drug classes for pain intensity also included anti-hemorrhagic agents (e.g., fostamatinib [tier 1: <italic toggle="yes">MST1R</italic> and <italic toggle="yes">FYN</italic>; tier 2: <italic toggle="yes">NEK4</italic>] and menadione [<italic toggle="yes">VKORC1</italic>]) (<xref rid="F4" ref-type="fig">Figure 4B</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 30</xref>).</p><p id="P58">Of the 7 genes associated with pain intensity in AAs, <italic toggle="yes">PPARD,</italic> which harbors the new genetic signal discovered in this study, is a tier-1 druggable candidate with 30 interacting drug classes (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 30</xref>). The <italic toggle="yes">PPARD</italic> negative modulator sulindac is an approved non-steroidal anti-inflammatory and antirheumatic drug used to treat osteoarthritis.</p></sec></sec><sec id="S23"><title>Discussion</title><p id="P59">We conducted the largest multi-ancestry, single-sample GWAS of pain intensity to date, comprising 112,968 AA, 436,683 EA, and 48,688 HA individuals. Cross-ancestry analyses identified 125 independent risk loci, of which 82 have not previously been associated with any pain phenotype. Although prior GWASs for chronic pain phenotypes have identified 99 loci<sup><xref rid="R23" ref-type="bibr">23</xref>-<xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R32" ref-type="bibr">32</xref></sup>, the study samples have largely been limited to EA individuals. The diversity of the MVP sample enabled us to identify novel association signals in both AAs (<italic toggle="yes">PPARD</italic>*rs9470000) and HAs (nearest genes <italic toggle="yes">RNU6-461P</italic>*rs146862033, <italic toggle="yes">RNU6-741P</italic>*rs1019597899).</p><p id="P60">Findings from gene set analysis, tissue enrichment, and cell-type specificity highlight novel biological pathways linking genetic variation to the etiopathology of pain. These functional analyses all implicate the brain, providing genetic support to the current understanding of the pathophysiology of pain severity<sup><xref rid="R93" ref-type="bibr">93</xref></sup>. Genes predominantly expressed in the CNS, particularly in the cerebellum, cerebellar hemisphere, and cortex region, rather than in the DRG, appear to play a salient role in modulating the intensity of pain, consistent with prior associations of sustained chronic pain intensity with increased activity in these brain regions<sup><xref rid="R94" ref-type="bibr">94</xref>-<xref rid="R96" ref-type="bibr">96</xref></sup>. Our findings are also consistent with prior reports<sup><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R97" ref-type="bibr">97</xref>,<xref rid="R98" ref-type="bibr">98</xref></sup> of enriched gene expression in brain that contribute to pain intensity in a dose- and time-dependent manner and may involve specific neuronal processes in brain regions implicated in emotional processing<sup><xref rid="R93" ref-type="bibr">93</xref></sup>. Evidence that GABAergic neurons are cells of specific interest is a key novel finding. GABA has long been implicated in the modulation and perception of pain<sup><xref rid="R99" ref-type="bibr">99</xref>-<xref rid="R101" ref-type="bibr">101</xref></sup> and previous work has implicated specific GABAergic activity in the midbrain as a modulator of pain and anxiety<sup><xref rid="R102" ref-type="bibr">102</xref></sup>. Altered GABA levels have been reported in individuals with various types of pain <sup><xref rid="R103" ref-type="bibr">103</xref>,<xref rid="R104" ref-type="bibr">104</xref></sup>, and have been associated with greater self-reported pain <sup><xref rid="R105" ref-type="bibr">105</xref></sup>. Targeting GABA functioning (e.g.,<sup><xref rid="R106" ref-type="bibr">106</xref></sup>), particularly in the brain regions enriched for pain intensity, may represent a novel therapeutic strategy.</p><p id="P61">Eleven of 156 prioritized genes encode druggable small molecules that are targets of licensed drugs or those in clinical trials, representing drug repurposing opportunities for treating chronic pain. We highlight <italic toggle="yes">GRK4</italic> and <italic toggle="yes">GRIA1,</italic> each with at least three lines of evidence supporting their involvement in chronic pain. <italic toggle="yes">GRK4</italic> encodes G protein-coupled receptor kinase 4 and has been linked with hypertension<sup><xref rid="R107" ref-type="bibr">107</xref></sup>, which is associated with chronic pain at the population level<sup><xref rid="R108" ref-type="bibr">108</xref>,<xref rid="R109" ref-type="bibr">109</xref></sup>. Of note, <italic toggle="yes">GRK4</italic> showed significant upregulation in the cerebellar hemisphere, fine maps to an intronic variant with &gt; 95% PP, and is a target of beta-blockers. The use of beta-blockers has been associated with reduced osteoarthritis pain scores, prescription analgesic use<sup><xref rid="R90" ref-type="bibr">90</xref></sup> and consultations for knee osteoarthritis, knee pain, and hip pain<sup><xref rid="R91" ref-type="bibr">91</xref></sup>. <italic toggle="yes">GRIA1</italic> encodes an ionotropic glutamate receptor subunit, an excitatory neurotransmitter receptor at many synapses in the CNS. Loss-of-function mutations in <italic toggle="yes">GRIA1</italic> are linked to neurodevelopmental impairments<sup><xref rid="R110" ref-type="bibr">110</xref>,<xref rid="R111" ref-type="bibr">111</xref></sup>. The <italic toggle="yes">GRIA1</italic> antagonist sevoflurane reduced pain in patients suffering from chronic venous ulcer<sup><xref rid="R112" ref-type="bibr">112</xref></sup>. However, clinical trials of topiramate (another drug target for <italic toggle="yes">GRIA1</italic>) for treating neuropathic chronic pain are inconclusive<sup><xref rid="R113" ref-type="bibr">113</xref></sup>. Research on the mechanisms that underlie the biology of these potential drug targets for <italic toggle="yes">GRK4</italic> and <italic toggle="yes">GRIA1</italic> and their effects on the onset and severity of chronic pain are warranted.</p><p id="P62">Pain intensity was strongly genetically correlated with other chronic pain phenotypes. Corroborating existing epidemiological studies on the comorbid nature of different pain conditions<sup><xref rid="R33" ref-type="bibr">33</xref></sup>, the strongest genetic correlations of pain intensity were with multisite chronic pain, followed by pain in specific bodily locations. In line with previous observations in GWASs of other pain-related phenotypes <sup><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R89" ref-type="bibr">89</xref></sup>, there were also positive genetic correlations of pain intensity with psychiatric disorders, substance use and use disorders, and anthropometric traits.</p><p id="P63">PheWAS findings in both the Yale-Penn sample &#8211; enriched for individuals with substance-related traits &#8211; and the PMBB &#8211; comprising a medical population &#8211; were prominent in EAs. These findings underscore the important influence of co-occurring substance-related, psychiatric, and medical pathology and educational achievement on the intensity of the pain experience. In contrast, the PRS generated from the pain intensity discovery sample in AAs yielded few associations in either of the target samples, which underscores the need for larger non-European samples to elucidate the genetic architecture of pain intensity.</p><p id="P64">Two-sample MR analysis supported causal associations between pain and multiple traits. Smoking has previously been associated with greater pain intensity, but studies can be confounded by socioeconomic factors, and a bi-directional relationship has been proposed<sup><xref rid="R114" ref-type="bibr">114</xref></sup>. Here, we show evidence for a causal relationship of pain on the number of cigarettes smoked per day, smoking initiation, and smoking cessation. In line with previous findings <sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R36" ref-type="bibr">36</xref></sup>, pain intensity had a bidirectional causal effect on the risk of both depression and neuroticism, suggesting that greater pain could predispose individuals to increased risk for these psychiatric disorders and vice versa. Supporting the positive genetic correlation between opioid use and pain intensity, MR showed evidence of a bidirectional causal effect between pain intensity and opioid use.</p><p id="P65">Our findings underscore the complex nature of pain intensity, with the hundreds of genetic loci contributing to the experience of pain identified here and in prior studies reflecting a substantial genetic contribution to pain-related traits. The evidence adduced here of pleiotropy of pain intensity with psychiatric traits such as neuroticism and depression reflects the contribution of non-physical factors to the experience of pain intensity. This is consistent with the observed significant tissue-group enrichment in CNS, the predominant gene expression findings in brain (including the hippocampus and limbic system), and the SNP-based enhancer enrichments in histone modification in brain tissues (including the dorsolateral prefrontal cortex, inferior temporal lobe, angular gyrus, and anterior caudate).</p><p id="P66">A limitation of the present study concerns the NRS phenotype. Although such a quantitative trait is more informative than a binary one (e.g., the presence of a specific pain diagnosis), it is based on subjective report. However, because the subjective experience of pain is a key defining feature of the clinical phenomenon<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R115" ref-type="bibr">115</xref></sup> the phenotype has high public health significance. Pain scores recorded by clerks and nurses in the clinical setting may consistently under report the patient&#8217;s response. In earlier work that compared self-reported pain from a direct patient survey to scores recorded in a VA clinical setting<sup>117</sup>, we found that, despite lower scores recorded in the clinic the two reports correlated well. Nonetheless, the imprecise measurement of pain intensity likely yields lower power for gene discovery. The routine assessment of pain severity provided a very large number of pain scores, which we reduced by taking the median of medians for each individual as a trait for GWAS. In subsequent analyses, we plan to evaluate alternative methods for characterizing pain severity (e.g., pain trajectories). Another limitation is that our sample comprises predominantly male veterans, which in view of well demonstrated sex differences in the experience and frequency of pain<sup><xref rid="R26" ref-type="bibr">26</xref></sup>, limits the application of the findings to the general population. Finally, although our sample was more diverse than prior GWAS of pain traits, analyses in the AA and HA samples were underpowered.</p><p id="P67">Despite these limitations, the large MVP sample and informative quantitative trait measured repeatedly within subjects enabled us to generate a proxy for chronic pain and identify many novel loci contributing to the trait. Downstream analyses localize the genetic effects largely to four CNS regions and using available single-cell RNAseq data specifically to GABAergic neurons. Combined with drug repurposing findings that implicate 20 druggable targets, the study provides a basis for studies of novel, non-opioid medications for use in alleviating chronic pain.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="media-1.docx" id="d64e1996" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD2" position="float" content-type="local-data" orientation="portrait"><label>Supplement 2</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="media-2.xlsx" id="d64e1999" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack id="S26"><title>Acknowledgements.</title><p id="P70">This work was supported by grants from the US Department of Veterans Affairs Biomedical Laboratory Research and Development Service (no. I01 BX003341 (to A.C.J. and H.R.K.)) and the VISN 4 Mental Illness Research, Education and Clinical Center (to H.R.K.); and NIH grants K01 AA028292 (to R.L.K.); and P30 DA046345 (to H.R.K.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the position or policy of the Department of Veterans Affairs or the US Government.</p><p id="P71">We acknowledge the Penn Medicine BioBank (PMBB) for providing data to generate polygenic risk scores and conduct PheWAS analyses and thank the patients of Penn Medicine who consented to participate in this research program. We would also like to thank the Penn Medicine BioBank team and Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is approved under IRB protocol# 813913 and supported by Perelman School of Medicine at University of Pennsylvania, a gift from the Smilow family, and the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA award number UL1TR001878.</p><p id="P72">This manuscript has been co-authored by UT-Battelle, LLC under Contract No. DE-AC05-00OR22725 with the U.S. Department of Energy. The United States Government retains and the publisher, by accepting the article for publication, acknowledges that the United States Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes. The Department of Energy will provide public access to these results of federally sponsored research in accordance with the DOE Public Access Plan (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://energy.gov/downloads/doe-public-access-plan" ext-link-type="uri">http://energy.gov/downloads/doe-public-access-plan</ext-link>).</p></ack><fn-group><fn id="FN2"><p id="P73">Ethics declarations</p><p id="P74">HRK is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies from Alkermes for an investigator-initiated study; and a member of the American Society of Clinical Psychopharmacology&#8217;s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. HRK and JG are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018. ES is a full-time employee of Regeneron Pharmaceuticals. The other authors have no disclosures to make.</p></fn></fn-group><sec sec-type="data-availability" id="S24"><title>Data Availability.</title><p id="P68">The full summary statistics from the meta-analyses will be available through dbGaP upon publication.</p></sec><sec sec-type="data-availability" id="S25"><title>Code Availability.</title><p id="P69">Imputation was performed using Minimac3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://genome.sph.umich.edu/wiki/Minimac3" ext-link-type="uri">https://genome.sph.umich.edu/wiki/Minimac3</ext-link>). GWAS was performed using PLINK2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.coggenomics.org/plink2" ext-link-type="uri">https://www.coggenomics.org/plink2</ext-link>). Meta-analyses were performed using METAL (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://genome.sph.umich.edu/wiki/METAL_Documentation" ext-link-type="uri">https://genome.sph.umich.edu/wiki/METAL_Documentation</ext-link>). GCTA-COJO (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cnsgenomics.com/software/gcta/#Overview" ext-link-type="uri">https://cnsgenomics.com/software/gcta/#Overview</ext-link>) was used for identification of independent loci. FUMA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://fuma.ctglab.nl/" ext-link-type="uri">https://fuma.ctglab.nl/</ext-link>) was used for gene association, functional enrichment and gene-set enrichment analyses. Transcriptomic and proteomic analyses were performed using FUSION (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/gusevlab/fusion_twas" ext-link-type="uri">https://github.com/gusevlab/fusion_twas</ext-link>). Chromatin accessibility analyses were performed using H-MAGMA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/thewonlab/H-MAGMA" ext-link-type="uri">https://github.com/thewonlab/H-MAGMA</ext-link>). LDSC (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/bulik/ldsc" ext-link-type="uri">https://github.com/bulik/ldsc</ext-link>) was used for heritability estimation, genetic correlation analysis (also using the CTG-VL; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://genoma.io/" ext-link-type="uri">https://genoma.io</ext-link>) and heritability enrichment analyses. Trans-ancestry genetic correlation was estimated using Popcorn (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/brielin/Popcorn" ext-link-type="uri">https://github.com/brielin/Popcorn</ext-link>). PRS analyses were performed using PRS-CS (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/getian107/PRScs" ext-link-type="uri">https://github.com/getian107/PRScs</ext-link>). PheWAS analyses were run using the PheWAS R package (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/PheWAS/PheWAS" ext-link-type="uri">https://github.com/PheWAS/PheWAS</ext-link>). The MendelianRandomization R package (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cran.r-project.org/web/packages/MendelianRandomization/index.html" ext-link-type="uri">https://cran.r-project.org/web/packages/MendelianRandomization/index.html</ext-link>) was used for MR analyses.</p></sec><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Raja</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Carr</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>M</given-names></name>, <etal/><article-title>The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises</article-title>. <source>PAIN</source>. <year>2020</year>;<volume>161</volume>(<issue>9</issue>). <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.lww.com/pain/Fulltext/2020/09000/The_revised_International_Association_for_the.6.aspx" ext-link-type="uri">https://journals.lww.com/pain/Fulltext/2020/09000/The_revised_International_Association_for_the.6.aspx</ext-link></comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000001939</pub-id><pub-id pub-id-type="pmcid">PMC7680716</pub-id><pub-id pub-id-type="pmid">32694387</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Scher</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Meador</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Van Cleave</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Reid</surname><given-names>MC</given-names></name>. <article-title>Moving Beyond Pain as the Fifth Vital Sign and Patient Satisfaction Scores to Improve Pain Care in the 21st Century</article-title>. <source>Pain Manag Nurs</source>. <year>2018</year>;<volume>19</volume>(<issue>2</issue>):<fpage>125</fpage>&#8211;<lpage>129</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pmn.2017.10.010</pub-id><pub-id pub-id-type="pmid">29249620</pub-id><pub-id pub-id-type="pmcid">PMC5878703</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nestler</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Waxman</surname><given-names>SG</given-names></name>. <article-title>Resilience to Stress and Resilience to Pain: Lessons from Molecular Neurobiology and Genetics</article-title>. <source>Trends in Molecular Medicine</source>. <year>2020</year>;<volume>26</volume>(<issue>10</issue>):<fpage>924</fpage>&#8211;<lpage>935</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molmed.2020.03.007</pub-id><pub-id pub-id-type="pmid">32976800</pub-id><pub-id pub-id-type="pmcid">PMC7519173</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yong</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Mullins</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Bhattacharyya</surname><given-names>N</given-names></name>. <article-title>Prevalence of chronic pain among adults in the United States</article-title>. <source>Pain</source>. <year>2022</year>;<volume>163</volume>(<issue>2</issue>):<fpage>e328</fpage>&#8211;<lpage>e332</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000002291</pub-id><pub-id pub-id-type="pmid">33990113</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tompkins</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Hobelmann</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Compton</surname><given-names>P</given-names></name>. <article-title>Providing chronic pain management in the &#8220;Fifth Vital Sign&#8221; Era: Historical and treatment perspectives on a modern-day medical dilemma</article-title>. <source>Drug and Alcohol Dependence</source>. <year>2017</year>;<volume>173</volume>:<fpage>S11</fpage>&#8211;<lpage>S21</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.12.002</pub-id><pub-id pub-id-type="pmid">28363315</pub-id><pub-id pub-id-type="pmcid">PMC5771233</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gaskin</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Richard</surname><given-names>P</given-names></name>. <article-title>The economic costs of pain in the United States</article-title>. <source>J Pain</source>. <year>2012</year>;<volume>13</volume>(<issue>8</issue>):<fpage>715</fpage>&#8211;<lpage>724</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpain.2012.03.009</pub-id><pub-id pub-id-type="pmid">22607834</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>James</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Abate</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Abate</surname><given-names>KH</given-names></name>, <etal/><article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990&#8211;2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title>. <source>The Lancet</source>. <year>2018</year>;<volume>392</volume>(<issue>10159</issue>):<fpage>1789</fpage>&#8211;<lpage>1858</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(18)32279-7</pub-id><pub-id pub-id-type="pmcid">PMC6227754</pub-id><pub-id pub-id-type="pmid">30496104</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Humphreys</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Shover</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>CM</given-names></name>, <etal/><article-title>Responding to the opioid crisis in North America and beyond: recommendations of the Stanford&#8211;Lancet Commission</article-title>. <source>The Lancet</source>. <year>2022</year>;<volume>399</volume>(<issue>10324</issue>):<fpage>555</fpage>&#8211;<lpage>604</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)02252-2</pub-id><pub-id pub-id-type="pmcid">PMC9261968</pub-id><pub-id pub-id-type="pmid">35122753</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Friedman</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>H</given-names></name>. <article-title>Evaluation of Increases in Drug Overdose Mortality Rates in the US by Race and Ethnicity Before and During the COVID-19 Pandemic</article-title>. <source>JAMA Psychiatry</source>. <year>2022</year>;<volume>79</volume>(<issue>4</issue>):<fpage>379</fpage>&#8211;<lpage>381</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2022.0004</pub-id><pub-id pub-id-type="pmid">35234815</pub-id><pub-id pub-id-type="pmcid">PMC8892360</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Maher</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Siah</surname><given-names>KW</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>AW</given-names></name>. <article-title>Estimates of Probabilities of Successful Development of Pain Medications: An Analysis of Pharmaceutical Clinical Development Programs from 2000 to 2020</article-title>. <source>Anesthesiology</source>. <year>2022</year>;<volume>137</volume>(<issue>2</issue>):<fpage>243</fpage>&#8211;<lpage>251</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ALN.0000000000004265</pub-id><pub-id pub-id-type="pmid">35504001</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ballantyne</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>NS</given-names></name>. <article-title>Efficacy of opioids for chronic pain: a review of the evidence</article-title>. <source>Clin J Pain</source>. <year>2008</year>;<volume>24</volume>(<issue>6</issue>):<fpage>469</fpage>&#8211;<lpage>478</lpage>. doi:<pub-id pub-id-type="doi">10.1097/AJP.0b013e31816b2f26</pub-id><pub-id pub-id-type="pmid">18574357</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cheatle</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>SR</given-names></name>. <article-title>Informed consent in opioid therapy: a potential obligation and opportunity</article-title>. <source>J Pain Symptom Manage</source>. <year>2012</year>;<volume>44</volume>(<issue>1</issue>):<fpage>105</fpage>&#8211;<lpage>116</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpainsymman.2011.06.015</pub-id><pub-id pub-id-type="pmid">22445273</pub-id><pub-id pub-id-type="pmcid">PMC3392420</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Els</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>TD</given-names></name>, <name name-style="western"><surname>Kunyk</surname><given-names>D</given-names></name>, <etal/><article-title>Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2017</year>;<volume>10</volume>(<issue>10</issue>):<fpage>CD012509</fpage>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD012509.pub2</pub-id><pub-id pub-id-type="pmid">29084357</pub-id><pub-id pub-id-type="pmcid">PMC6485910</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="book"><name name-style="western"><surname>McDonagh</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Selph</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Buckley</surname><given-names>D</given-names></name>. <source>Nonopioid Pharmacologic Treatments for Chronic Pain</source>. <publisher-loc>Rockville (MD)</publisher-loc>: <publisher-name>Agency for Healthcare Research and Quality (US)</publisher-name>; <year>2020</year>. Available from: <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK556277/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK556277/</ext-link></comment><pub-id pub-id-type="pmid">32338847</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nelson</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Tipney</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Painter</surname><given-names>JL</given-names></name>, <etal/><article-title>The support of human genetic evidence for approved drug indications</article-title>. <source>Nature Genetics</source>. <year>2015</year>;<volume>47</volume>(<issue>8</issue>):<fpage>856</fpage>&#8211;<lpage>860</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.3314</pub-id><pub-id pub-id-type="pmid">26121088</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>King</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Degner</surname><given-names>JF</given-names></name>. <article-title>Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval</article-title>. <source>PLoS Genet</source>. <year>2019</year>;<volume>15</volume>(<issue>12</issue>):<fpage>e1008489</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pgen.1008489</pub-id><pub-id pub-id-type="pmid">31830040</pub-id><pub-id pub-id-type="pmcid">PMC6907751</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pushpakom</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Iorio</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Eyers</surname><given-names>PA</given-names></name>, <etal/><article-title>Drug repurposing: progress, challenges and recommendations</article-title>. <source>Nature Reviews Drug Discovery</source>. <year>2019</year>;<volume>18</volume>(<issue>1</issue>):<fpage>41</fpage>&#8211;<lpage>58</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrd.2018.168</pub-id><pub-id pub-id-type="pmid">30310233</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nielsen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Knudsen</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Steingr&#237;msd&#243;ttir</surname><given-names>&#211;</given-names></name>. <article-title>Twin studies of pain</article-title>. <source>Clinical Genetics</source>. <year>2012</year>;<volume>82</volume>(<issue>4</issue>):<fpage>331</fpage>&#8211;<lpage>340</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1399-0004.2012.01938.x</pub-id><pub-id pub-id-type="pmid">22823509</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sexton</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Cox</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wood</surname><given-names>JN</given-names></name>. <article-title>The Genetics of Pain: Implications for Therapeutics</article-title>. <source>Annu Rev Pharmacol Toxicol</source>. <year>2018</year>;<volume>58</volume>(<issue>1</issue>):<fpage>123</fpage>&#8211;<lpage>142</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010617-052554</pub-id><pub-id pub-id-type="pmid">28968191</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Abboud</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Duveau</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bouali-Benazzouz</surname><given-names>R</given-names></name>, <etal/><article-title>Animal models of pain: Diversity and benefits</article-title>. <source>Journal of Neuroscience Methods</source>. <year>2021</year>;<volume>348</volume>:<fpage>108997</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jneumeth.2020.108997</pub-id><pub-id pub-id-type="pmid">33188801</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Meng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Palmer</surname><given-names>CNA</given-names></name>, <etal/><article-title>Genome-wide association study of knee pain identifies associations with GDF5 and COL27A1 in UK Biobank</article-title>. <source>Communications Biology</source>. <year>2019</year>;<volume>2</volume>(<issue>1</issue>):<fpage>321</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s42003-019-0568-2</pub-id><pub-id pub-id-type="pmid">31482140</pub-id><pub-id pub-id-type="pmcid">PMC6713725</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Meng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>BW</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>C</given-names></name>, <etal/><article-title>A genome-wide association study finds genetic variants associated with neck or shoulder pain in UK Biobank</article-title>. <source>Human Molecular Genetics</source>. <year>2020</year>;<volume>29</volume>(<issue>8</issue>):<fpage>1396</fpage>&#8211;<lpage>1404</lpage>. doi:<pub-id pub-id-type="doi">10.1093/hmg/ddaa058</pub-id><pub-id pub-id-type="pmid">32246137</pub-id><pub-id pub-id-type="pmcid">PMC7254846</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Suri</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Palmer</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Tsepilov</surname><given-names>YA</given-names></name>, <etal/><article-title>Genome-wide meta-analysis of 158,000 individuals of European ancestry identifies three loci associated with chronic back pain</article-title>. <source>PLoS Genet</source>. <year>2018</year>;<volume>14</volume>(<issue>9</issue>):<fpage>e1007601</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pgen.1007601</pub-id><pub-id pub-id-type="pmid">30261039</pub-id><pub-id pub-id-type="pmcid">PMC6159857</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Freidin</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Tsepilov</surname><given-names>YA</given-names></name>, <name name-style="western"><surname>Palmer</surname><given-names>M</given-names></name>, <etal/><article-title>Insight into the genetic architecture of back pain and its risk factors from a study of 509,000 individuals</article-title>. <source>Pain</source>. <year>2019</year>;<volume>160</volume>(<issue>6</issue>):<fpage>1361</fpage>&#8211;<lpage>1373</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000001514</pub-id><pub-id pub-id-type="pmid">30747904</pub-id><pub-id pub-id-type="pmcid">PMC7066867</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Johnston</surname><given-names>KJA</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Nicholl</surname><given-names>BI</given-names></name>, <etal/><article-title>Genome-wide association study of multisite chronic pain in UK Biobank</article-title>. <source>PLOS Genetics</source>. <year>2019</year>;<volume>15</volume>(<issue>6</issue>):<fpage>e1008164</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pgen.1008164</pub-id><pub-id pub-id-type="pmid">31194737</pub-id><pub-id pub-id-type="pmcid">PMC6592570</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Johnston</surname><given-names>KJA</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ray</surname><given-names>PR</given-names></name>, <etal/><article-title>Sex-stratified genome-wide association study of multisite chronic pain in UK Biobank</article-title>. <source>PLoS Genet</source>. <year>2021</year>;<volume>17</volume>(<issue>4</issue>):<fpage>e1009428</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pgen.1009428</pub-id><pub-id pub-id-type="pmid">33830993</pub-id><pub-id pub-id-type="pmcid">PMC8031124</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mocci</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Dorsey</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Ament</surname><given-names>SA</given-names></name>. <article-title>GWAS meta-analysis reveals dual neuronal and immunological etiology for pain susceptibility</article-title>. <source>medRxiv</source>. Published online <month>January</month><day>1</day>, <year>2021</year>:2021.08.23.21262510. doi:<pub-id pub-id-type="doi">10.1101/2021.08.23.21262510</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rahman</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Winsvold</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Chavez Chavez</surname><given-names>SO</given-names></name>, <etal/><article-title>Genome-wide association study identifies RNF123 locus as associated with chronic widespread musculoskeletal pain</article-title>. <source>Ann Rheum Dis</source>. <year>2021</year>;<volume>80</volume>(<issue>9</issue>):<fpage>1227</fpage>&#8211;<lpage>1235</lpage>. doi:<pub-id pub-id-type="doi">10.1136/annrheumdis-2020-219624</pub-id><pub-id pub-id-type="pmid">33926923</pub-id><pub-id pub-id-type="pmcid">PMC8372387</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Meng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Hebert</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Deary</surname><given-names>IJ</given-names></name>, <name name-style="western"><surname>McIntosh</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>BH</given-names></name>. <article-title>A Genome-Wide Association Study Finds Genetic Associations with Broadly-Defined Headache in UK Biobank (N=223,773)</article-title>. <source>EBioMedicine</source>. <year>2018</year>;<volume>28</volume>:<fpage>180</fpage>&#8211;<lpage>186</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ebiom.2018.01.023</pub-id><pub-id pub-id-type="pmid">29397368</pub-id><pub-id pub-id-type="pmcid">PMC5898025</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tachmazidou</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Hatzikotoulas</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Southam</surname><given-names>L</given-names></name>, <etal/><article-title>Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data</article-title>. <source>Nature Genetics</source>. <year>2019</year>;<volume>51</volume>(<issue>2</issue>):<fpage>230</fpage>&#8211;<lpage>236</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41588-018-0327-1</pub-id><pub-id pub-id-type="pmid">30664745</pub-id><pub-id pub-id-type="pmcid">PMC6400267</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Boer</surname><given-names>CG</given-names></name>, <name name-style="western"><surname>Hatzikotoulas</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Southam</surname><given-names>L</given-names></name>, <etal/><article-title>Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations</article-title>. <source>Cell</source>. <year>2021</year>;<volume>184</volume>(<issue>18</issue>):<fpage>4784</fpage>&#8211;<lpage>4818.e17</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2021.07.038</pub-id><pub-id pub-id-type="pmid">34450027</pub-id><pub-id pub-id-type="pmcid">PMC8459317</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zorina-Lichtenwalter</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Parisien</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Diatchenko</surname><given-names>L</given-names></name>. <article-title>Genetic studies of human neuropathic pain conditions: a review</article-title>. <source>Pain</source>. <year>2018</year>;<volume>159</volume>(<issue>3</issue>):<fpage>583</fpage>&#8211;<lpage>594</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000001099</pub-id><pub-id pub-id-type="pmid">29240606</pub-id><pub-id pub-id-type="pmcid">PMC5828382</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Meng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Reel</surname><given-names>P</given-names></name>, <etal/><article-title>Genetic correlations between pain phenotypes and depression and neuroticism</article-title>. <source>European Journal of Human Genetics</source>. <year>2020</year>;<volume>28</volume>(<issue>3</issue>):<fpage>358</fpage>&#8211;<lpage>366</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41431-019-0530-2</pub-id><pub-id pub-id-type="pmid">31659249</pub-id><pub-id pub-id-type="pmcid">PMC7028719</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zorina-Lichtenwalter</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bango</surname><given-names>CI</given-names></name>, <name name-style="western"><surname>Van Oudenhove</surname><given-names>L</given-names></name>, <etal/><article-title>Identification and characterization of genetic risk shared across 24 chronic pain conditions in the UK Biobank</article-title>. <source>medRxiv</source>. Published online <month>January</month><day>1</day>, <year>2022</year>:2022.06.28.22277025. doi:<pub-id pub-id-type="doi">10.1101/2022.06.28.22277025</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>H&#228;gg</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name>. <article-title>Reciprocal interaction between depression and pain: results from a comprehensive bidirectional Mendelian randomization study and functional annotation analysis</article-title>. <source>Pain</source>. <year>2022</year>;<volume>163</volume>(<issue>1</issue>):<fpage>e40</fpage>&#8211;<lpage>e48</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000002305</pub-id><pub-id pub-id-type="pmid">34924553</pub-id><pub-id pub-id-type="pmcid">PMC8675051</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Farrell</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Kho</surname><given-names>PF</given-names></name>, <name name-style="western"><surname>Lundberg</surname><given-names>M</given-names></name>, <etal/><article-title>A Shared Genetic Signature for Common Chronic Pain Conditions and its Impact on Biopsychosocial Traits</article-title>. <source>The Journal of Pain</source>. Published online <month>October</month><day>14</day>, <year>2022</year>. doi:<pub-id pub-id-type="doi">10.1016/j.jpain.2022.10.005</pub-id><pub-id pub-id-type="pmid">36252619</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Troiani</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Crist</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Doyle</surname><given-names>GA</given-names></name>, <etal/><article-title>Genetics and prescription opioid use (GaPO): study design for consenting a cohort from an existing biobank to identify clinical and genetic factors influencing prescription opioid use and abuse</article-title>. <source>BMC Med Genomics</source>. <year>2021</year>;<volume>14</volume>(<issue>1</issue>):<fpage>253</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12920-021-01100-z</pub-id><pub-id pub-id-type="pmid">34702274</pub-id><pub-id pub-id-type="pmcid">PMC8547564</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gaziano</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Concato</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Brophy</surname><given-names>M</given-names></name>, <etal/><article-title>Million Veteran Program: A mega-biobank to study genetic influences on health and disease</article-title>. <source>Journal of Clinical Epidemiology</source>. <year>2016</year>;<volume>70</volume>:<fpage>214</fpage>&#8211;<lpage>223</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jclinepi.2015.09.016</pub-id><pub-id pub-id-type="pmid">26441289</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Luther</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Finch</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Bouayad</surname><given-names>L</given-names></name>, <etal/><article-title>Measuring pain care quality in the Veterans Health Administration primary care setting</article-title>. <source>PAIN</source>. <year>2022</year>;<volume>163</volume>(<issue>6</issue>). <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.lww.com/pain/Fulltext/2022/06000/Measuring_pain_care_quality_in_the_Veterans_Health.5.aspx" ext-link-type="uri">https://journals.lww.com/pain/Fulltext/2022/06000/Measuring_pain_care_quality_in_the_Veterans_Health.5.aspx</ext-link></comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000002477</pub-id><pub-id pub-id-type="pmcid">PMC8920945</pub-id><pub-id pub-id-type="pmid">34724683</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Farrar</surname><given-names>JT</given-names></name>. <article-title>A consideration of differences in pain scales used in clinical trials</article-title>. <source>PAIN</source>. <year>2022</year>;<volume>163</volume>(<issue>12</issue>). <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.lww.com/pain/Fulltext/2022/12000/A_consideration_of_differences_in_pain_scales_used.1.aspx" ext-link-type="uri">https://journals.lww.com/pain/Fulltext/2022/12000/A_consideration_of_differences_in_pain_scales_used.1.aspx</ext-link></comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000002691</pub-id><pub-id pub-id-type="pmid">35580306</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ferreira-Valente</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Pais-Ribeiro</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>MP</given-names></name>. <article-title>Validity of four pain intensity rating scales</article-title>. <source>Pain</source>. <year>2011</year>;<volume>152</volume>(<issue>10</issue>):<fpage>2399</fpage>&#8211;<lpage>2404</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pain.2011.07.005</pub-id><pub-id pub-id-type="pmid">21856077</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Euasobhon</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Atisook</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bumrungchatudom</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zinboonyahgoon</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Saisavoey</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>MP</given-names></name>. <article-title>Reliability and responsivity of pain intensity scales in individuals with chronic pain</article-title>. <source>PAIN</source>. <year>2022</year>;<volume>163</volume>(<issue>12</issue>). <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.lww.com/pain/Fulltext/2022/12000/Reliability_and_responsivity_of_pain_intensity.6.aspx" ext-link-type="uri">https://journals.lww.com/pain/Fulltext/2022/12000/Reliability_and_responsivity_of_pain_intensity.6.aspx</ext-link></comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000002692</pub-id><pub-id pub-id-type="pmid">35584261</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Edlund</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Austen</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Sullivan</surname><given-names>MD</given-names></name>, <etal/><article-title>Patterns of opioid use for chronic noncancer pain in the Veterans Health Administration from 2009 to 2011</article-title>. <source>Pain</source>. <year>2014</year>;<volume>155</volume>(<issue>11</issue>):<fpage>2337</fpage>&#8211;<lpage>2343</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pain.2014.08.033</pub-id><pub-id pub-id-type="pmid">25180008</pub-id><pub-id pub-id-type="pmcid">PMC4252255</pub-id></mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><article-title>Department of Veterans Affairs</article-title>. <source>Pain Management - VHA Directive 2009&#8211;053</source>. Published online <month>October</month><day>28</day>, <year>2009</year>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.va.gov/painmanagement/docs/vha09paindirective.pdf" ext-link-type="uri">https://www.va.gov/painmanagement/docs/vha09paindirective.pdf</ext-link></comment></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hunter-Zinck</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>M</given-names></name>, <etal/><article-title>Genotyping Array Design and Data Quality Control in the Million Veteran Program</article-title>. <source>The American Journal of Human Genetics</source>. <year>2020</year>;<volume>106</volume>(<issue>4</issue>):<fpage>535</fpage>&#8211;<lpage>548</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajhg.2020.03.004</pub-id><pub-id pub-id-type="pmid">32243820</pub-id><pub-id pub-id-type="pmcid">PMC7118558</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Delaneau</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Zagury</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Marchini</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Dermitzakis</surname><given-names>ET</given-names></name>. <article-title>Accurate, scalable and integrative haplotype estimation</article-title>. <source>Nature Communications</source>. <year>2019</year>;<volume>10</volume>(<issue>1</issue>):<fpage>5436</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-13225-y</pub-id><pub-id pub-id-type="pmcid">PMC6882857</pub-id><pub-id pub-id-type="pmid">31780650</pub-id></mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Das</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Forer</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sch&#246;nherr</surname><given-names>S</given-names></name>, <etal/><article-title>Next-generation genotype imputation service and methods</article-title>. <source>Nature Genetics</source>. <year>2016</year>;<volume>48</volume>(<issue>10</issue>):<fpage>1284</fpage>&#8211;<lpage>1287</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.3656</pub-id><pub-id pub-id-type="pmid">27571263</pub-id><pub-id pub-id-type="pmcid">PMC5157836</pub-id></mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Auton</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Abecasis</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Altshuler</surname><given-names>DM</given-names></name>, <etal/><article-title>A global reference for human genetic variation</article-title>. <source>Nature</source>. <year>2015</year>;<volume>526</volume>(<issue>7571</issue>):<fpage>68</fpage>&#8211;<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature15393</pub-id><pub-id pub-id-type="pmid">26432245</pub-id><pub-id pub-id-type="pmcid">PMC4750478</pub-id></mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Lynch</surname><given-names>J</given-names></name>, <etal/><article-title>Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies</article-title>. <source>The American Journal of Human Genetics</source>. <year>2019</year>;<volume>105</volume>(<issue>4</issue>):<fpage>763</fpage>&#8211;<lpage>772</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajhg.2019.08.012</pub-id><pub-id pub-id-type="pmid">31564439</pub-id><pub-id pub-id-type="pmcid">PMC6817526</pub-id></mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chang</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Chow</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Tellier</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Vattikuti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Purcell</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JJ</given-names></name>. <article-title>Second-generation PLINK: rising to the challenge of larger and richer datasets</article-title>. <source>GigaScience</source>. <year>2015</year>;<volume>4</volume>(<issue>1</issue>):s13742-015-0047-0048. doi:<pub-id pub-id-type="doi">10.1186/s13742-015-0047-8</pub-id><pub-id pub-id-type="pmcid">PMC4342193</pub-id><pub-id pub-id-type="pmid">25722852</pub-id></mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Willer</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Abecasis</surname><given-names>GR</given-names></name>. <article-title>METAL: fast and efficient meta-analysis of genomewide association scans</article-title>. <source>Bioinformatics</source>. <year>2010</year>;<volume>26</volume>(<issue>17</issue>):<fpage>2190</fpage>&#8211;<lpage>2191</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btq340</pub-id><pub-id pub-id-type="pmid">20616382</pub-id><pub-id pub-id-type="pmcid">PMC2922887</pub-id></mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Taskesen</surname><given-names>E</given-names></name>, <name name-style="western"><surname>van Bochoven</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Posthuma</surname><given-names>D</given-names></name>. <article-title>Functional mapping and annotation of genetic associations with FUMA</article-title>. <source>Nature Communications</source>. <year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1826</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-017-01261-5</pub-id><pub-id pub-id-type="pmcid">PMC5705698</pub-id><pub-id pub-id-type="pmid">29184056</pub-id></mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Goddard</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Visscher</surname><given-names>PM</given-names></name>. <article-title>GCTA: a tool for genome-wide complex trait analysis</article-title>. <source>Am J Hum Genet</source>. <year>2011</year>;<volume>88</volume>(<issue>1</issue>):<fpage>76</fpage>&#8211;<lpage>82</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajhg.2010.11.011</pub-id><pub-id pub-id-type="pmid">21167468</pub-id><pub-id pub-id-type="pmcid">PMC3014363</pub-id></mixed-citation></ref><ref id="R54"><label>54.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Benner</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Spencer</surname><given-names>CCA</given-names></name>, <name name-style="western"><surname>Havulinna</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Salomaa</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ripatti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pirinen</surname><given-names>M</given-names></name>. <article-title>FINEMAP: efficient variable selection using summary data from genome-wide association studies</article-title>. <source>Bioinformatics</source>. <year>2016</year>;<volume>32</volume>(<issue>10</issue>):<fpage>1493</fpage>&#8211;<lpage>1501</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btw018</pub-id><pub-id pub-id-type="pmid">26773131</pub-id><pub-id pub-id-type="pmcid">PMC4866522</pub-id></mixed-citation></ref><ref id="R55"><label>55.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Benner</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Havulinna</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>J&#228;rvelin</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Salomaa</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ripatti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pirinen</surname><given-names>M</given-names></name>. <article-title>Prospects of Fine-Mapping Trait-Associated Genomic Regions by Using Summary Statistics from Genome-wide Association Studies</article-title>. <source>The American Journal of Human Genetics</source>. <year>2017</year>;<volume>101</volume>(<issue>4</issue>):<fpage>539</fpage>&#8211;<lpage>551</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajhg.2017.08.012</pub-id><pub-id pub-id-type="pmid">28942963</pub-id><pub-id pub-id-type="pmcid">PMC5630179</pub-id></mixed-citation></ref><ref id="R56"><label>56.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bulik-Sullivan</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Loh</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Finucane</surname><given-names>HK</given-names></name>, <etal/><article-title>LD Score regression distinguishes confounding from polygenicity in genome-wide association studies</article-title>. <source>Nature Genetics</source>. <year>2015</year>;<volume>47</volume>(<issue>3</issue>):<fpage>291</fpage>&#8211;<lpage>295</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.3211</pub-id><pub-id pub-id-type="pmid">25642630</pub-id><pub-id pub-id-type="pmcid">PMC4495769</pub-id></mixed-citation></ref><ref id="R57"><label>57.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Altshuler</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Gibbs</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Peltonen</surname><given-names>L</given-names></name>, <etal/><article-title>Integrating common and rare genetic variation in diverse human populations</article-title>. <source>Nature</source>. <year>2010</year>;<volume>467</volume>(<issue>7311</issue>):<fpage>52</fpage>&#8211;<lpage>58</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature09298</pub-id><pub-id pub-id-type="pmid">20811451</pub-id><pub-id pub-id-type="pmcid">PMC3173859</pub-id></mixed-citation></ref><ref id="R58"><label>58.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <etal/><article-title>Estimating heritability and its enrichment in tissue-specific gene sets in admixed populations</article-title>. <source>Human Molecular Genetics</source>. <year>2021</year>;<volume>30</volume>(<issue>16</issue>):<fpage>1521</fpage>&#8211;<lpage>1534</lpage>. doi:<pub-id pub-id-type="doi">10.1093/hmg/ddab130</pub-id><pub-id pub-id-type="pmid">33987664</pub-id><pub-id pub-id-type="pmcid">PMC8330913</pub-id></mixed-citation></ref><ref id="R59"><label>59.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Finucane</surname><given-names>HK</given-names></name>, <name name-style="western"><surname>Bulik-Sullivan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Gusev</surname><given-names>A</given-names></name>, <etal/><article-title>Partitioning heritability by functional annotation using genome-wide association summary statistics</article-title>. <source>Nature Genetics</source>. <year>2015</year>;<volume>47</volume>(<issue>11</issue>):<fpage>1228</fpage>&#8211;<lpage>1235</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.3404</pub-id><pub-id pub-id-type="pmid">26414678</pub-id><pub-id pub-id-type="pmcid">PMC4626285</pub-id></mixed-citation></ref><ref id="R60"><label>60.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Finucane</surname><given-names>HK</given-names></name>, <name name-style="western"><surname>Reshef</surname><given-names>YA</given-names></name>, <name name-style="western"><surname>Anttila</surname><given-names>V</given-names></name>, <etal/><article-title>Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types</article-title>. <source>Nature Genetics</source>. <year>2018</year>;<volume>50</volume>(<issue>4</issue>):<fpage>621</fpage>&#8211;<lpage>629</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41588-018-0081-4</pub-id><pub-id pub-id-type="pmid">29632380</pub-id><pub-id pub-id-type="pmcid">PMC5896795</pub-id></mixed-citation></ref><ref id="R61"><label>61.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>The GTEx consortium</surname><given-names>Aguet Fran&#231;ois</given-names></name>, <name name-style="western"><surname>Shankara</surname><given-names>Anand</given-names></name>, <etal/><article-title>The GTEx Consortium atlas of genetic regulatory effects across human tissues</article-title>. <source>Science</source>. <year>2020</year>;<volume>369</volume>(<issue>6509</issue>):<fpage>1318</fpage>&#8211;<lpage>1330</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aaz1776</pub-id><pub-id pub-id-type="pmid">32913098</pub-id><pub-id pub-id-type="pmcid">PMC7737656</pub-id></mixed-citation></ref><ref id="R62"><label>62.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bernstein</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Stamatoyannopoulos</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Costello</surname><given-names>JF</given-names></name>, <etal/><article-title>The NIH Roadmap Epigenomics Mapping Consortium</article-title>. <source>Nat Biotechnol</source>. <year>2010</year>;<volume>28</volume>(<issue>10</issue>):<fpage>1045</fpage>&#8211;<lpage>1048</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nbt1010-1045</pub-id><pub-id pub-id-type="pmid">20944595</pub-id><pub-id pub-id-type="pmcid">PMC3607281</pub-id></mixed-citation></ref><ref id="R63"><label>63.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>de Leeuw</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Mooij</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Heskes</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Posthuma</surname><given-names>D</given-names></name>. <article-title>MAGMA: Generalized Gene-Set Analysis of GWAS Data</article-title>. <source>PLOS Computational Biology</source>. <year>2015</year>;<volume>11</volume>(<issue>4</issue>):<fpage>e1004219</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pcbi.1004219</pub-id><pub-id pub-id-type="pmid">25885710</pub-id><pub-id pub-id-type="pmcid">PMC4401657</pub-id></mixed-citation></ref><ref id="R64"><label>64.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sey</surname><given-names>NYA</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mah</surname><given-names>W</given-names></name>, <etal/><article-title>A computational tool (H-MAGMA) for improved prediction of brain-disorder risk genes by incorporating brain chromatin interaction profiles</article-title>. <source>Nature Neuroscience</source>. <year>2020</year>;<volume>23</volume>(<issue>4</issue>):<fpage>583</fpage>&#8211;<lpage>593</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41593-020-0603-0</pub-id><pub-id pub-id-type="pmid">32152537</pub-id><pub-id pub-id-type="pmcid">PMC7131892</pub-id></mixed-citation></ref><ref id="R65"><label>65.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rajarajan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Borrman</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>W</given-names></name>, <etal/><article-title>Neuron-specific signatures in the chromosomal connectome associated with schizophrenia risk</article-title>. <source>Science</source>. <year>2018</year>;<volume>362</volume>(<issue>6420</issue>). doi:<pub-id pub-id-type="doi">10.1126/science.aat4311</pub-id><pub-id pub-id-type="pmcid">PMC6408958</pub-id><pub-id pub-id-type="pmid">30545851</pub-id></mixed-citation></ref><ref id="R66"><label>66.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Liberzon</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Birger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Thorvaldsd&#243;ttir</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ghandi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mesirov</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Tamayo</surname><given-names>P</given-names></name>. <article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title>. <source>Cell Syst</source>. <year>2015</year>;<volume>1</volume>(<issue>6</issue>):<fpage>417</fpage>&#8211;<lpage>425</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id><pub-id pub-id-type="pmid">26771021</pub-id><pub-id pub-id-type="pmcid">PMC4707969</pub-id></mixed-citation></ref><ref id="R67"><label>67.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Umi&#263;evi&#263; Mirkov</surname><given-names>M</given-names></name>, <name name-style="western"><surname>de Leeuw</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>van den Heuvel</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Posthuma</surname><given-names>D</given-names></name>. <article-title>Genetic mapping of cell type specificity for complex traits</article-title>. <source>Nature Communications</source>. <year>2019</year>;<volume>10</volume>(<issue>1</issue>):<fpage>3222</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-11181-1</pub-id><pub-id pub-id-type="pmcid">PMC6642112</pub-id><pub-id pub-id-type="pmid">31324783</pub-id></mixed-citation></ref><ref id="R68"><label>68.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wingo</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gerasimov</surname><given-names>ES</given-names></name>, <etal/><article-title>Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer&#8217;s disease pathogenesis</article-title>. <source>Nature Genetics</source>. <year>2021</year>;<volume>53</volume>(<issue>2</issue>):<fpage>143</fpage>&#8211;<lpage>146</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41588-020-00773-z</pub-id><pub-id pub-id-type="pmid">33510477</pub-id><pub-id pub-id-type="pmcid">PMC8130821</pub-id></mixed-citation></ref><ref id="R69"><label>69.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fromer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Roussos</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sieberts</surname><given-names>SK</given-names></name>, <etal/><article-title>Gene expression elucidates functional impact of polygenic risk for schizophrenia</article-title>. <source>Nature Neuroscience</source>. <year>2016</year>;<volume>19</volume>(<issue>11</issue>):<fpage>1442</fpage>&#8211;<lpage>1453</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nn.4399</pub-id><pub-id pub-id-type="pmid">27668389</pub-id><pub-id pub-id-type="pmcid">PMC5083142</pub-id></mixed-citation></ref><ref id="R70"><label>70.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wingo</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gerasimov</surname><given-names>ES</given-names></name>, <etal/><article-title>Shared mechanisms across the major psychiatric and neurodegenerative diseases</article-title>. <source>Nature Communications</source>. <year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>4314</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-022-31873-5</pub-id><pub-id pub-id-type="pmcid">PMC9325708</pub-id><pub-id pub-id-type="pmid">35882878</pub-id></mixed-citation></ref><ref id="R71"><label>71.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gusev</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ko</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>H</given-names></name>, <etal/><article-title>Integrative approaches for large-scale transcriptome-wide association studies</article-title>. <source>Nature Genetics</source>. <year>2016</year>;<volume>48</volume>(<issue>3</issue>):<fpage>245</fpage>&#8211;<lpage>252</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.3506</pub-id><pub-id pub-id-type="pmid">26854917</pub-id><pub-id pub-id-type="pmcid">PMC4767558</pub-id></mixed-citation></ref><ref id="R72"><label>72.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Giambartolomei</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vukcevic</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Schadt</surname><given-names>EE</given-names></name>, <etal/><article-title>Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics</article-title>. <source>PLOS Genetics</source>. <year>2014</year>;<volume>10</volume>(<issue>5</issue>):<fpage>e1004383</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pgen.1004383</pub-id><pub-id pub-id-type="pmid">24830394</pub-id><pub-id pub-id-type="pmcid">PMC4022491</pub-id></mixed-citation></ref><ref id="R73"><label>73.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>H</given-names></name>, <etal/><article-title>Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets</article-title>. <source>Nature Genetics</source>. <year>2016</year>;<volume>48</volume>(<issue>5</issue>):<fpage>481</fpage>&#8211;<lpage>487</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.3538</pub-id><pub-id pub-id-type="pmid">27019110</pub-id></mixed-citation></ref><ref id="R74"><label>74.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Qi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>H</given-names></name>, <etal/><article-title>Genetic control of RNA splicing and its distinct role in complex trait variation</article-title>. <source>Nature Genetics</source>. <year>2022</year>;<volume>54</volume>(<issue>9</issue>):<fpage>1355</fpage>&#8211;<lpage>1363</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41588-022-01154-4</pub-id><pub-id pub-id-type="pmid">35982161</pub-id><pub-id pub-id-type="pmcid">PMC9470536</pub-id></mixed-citation></ref><ref id="R75"><label>75.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ray</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Torck</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Quigley</surname><given-names>L</given-names></name>, <etal/><article-title>Comparative transcriptome profiling of the human and mouse dorsal root ganglia: an RNA-seq&#8211;based resource for pain and sensory neuroscience research</article-title>. <source>PAIN</source>. <year>2018</year>;<volume>159</volume>(<issue>7</issue>). <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.lww.com/pain/Fulltext/2018/07000/Comparative_transcriptome_profiling_of_the_human.16.aspx" ext-link-type="uri">https://journals.lww.com/pain/Fulltext/2018/07000/Comparative_transcriptome_profiling_of_the_human.16.aspx</ext-link></comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000001217</pub-id><pub-id pub-id-type="pmcid">PMC6008200</pub-id><pub-id pub-id-type="pmid">29561359</pub-id></mixed-citation></ref><ref id="R76"><label>76.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Finan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gaulton</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kruger</surname><given-names>FA</given-names></name>, <etal/><article-title>The druggable genome and support for target identification and validation in drug development</article-title>. <source>Sci Transl Med</source>. <year>2017</year>;<volume>9</volume>(<issue>383</issue>). doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.aag1166</pub-id><pub-id pub-id-type="pmcid">PMC6321762</pub-id><pub-id pub-id-type="pmid">28356508</pub-id></mixed-citation></ref><ref id="R77"><label>77.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gaulton</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bellis</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Bento</surname><given-names>AP</given-names></name>, <etal/><article-title>ChEMBL: a large-scale bioactivity database for drug discovery</article-title>. <source>Nucleic Acids Res</source>. <year>2012</year>;<volume>40</volume>(<issue>Database issue</issue>):<fpage>D1100</fpage>&#8211;<lpage>1107</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkr777</pub-id><pub-id pub-id-type="pmid">21948594</pub-id><pub-id pub-id-type="pmcid">PMC3245175</pub-id></mixed-citation></ref><ref id="R78"><label>78.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cotto</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Wagner</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>YY</given-names></name>, <etal/><article-title>DGIdb 3.0: a redesign and expansion of the drug&#8211;gene interaction database</article-title>. <source>Nucleic Acids Research</source>. <year>2018</year>;<volume>46</volume>(<issue>D1</issue>):<fpage>D1068</fpage>&#8211;<lpage>D1073</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkx1143</pub-id><pub-id pub-id-type="pmid">29156001</pub-id><pub-id pub-id-type="pmcid">PMC5888642</pub-id></mixed-citation></ref><ref id="R79"><label>79.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cu&#233;llar-Partida</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Lundberg</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kho</surname><given-names>PF</given-names></name>, <etal/><article-title>Complex-Traits Genetics Virtual Lab: A community-driven web platform for post-GWAS analyses</article-title>. <source>bioRxiv</source>. Published online <month>January</month><day>1</day>, <year>2019</year>:<fpage>518027</fpage>. doi:<pub-id pub-id-type="doi">10.1101/518027</pub-id></mixed-citation></ref><ref id="R80"><label>80.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brown</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Zaitlen</surname><given-names>N</given-names></name>. <article-title>Transethnic Genetic-Correlation Estimates from Summary Statistics</article-title>. <source>The American Journal of Human Genetics</source>. <year>2016</year>;<volume>99</volume>(<issue>1</issue>):<fpage>76</fpage>&#8211;<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajhg.2016.05.001</pub-id><pub-id pub-id-type="pmid">27321947</pub-id><pub-id pub-id-type="pmcid">PMC5005434</pub-id></mixed-citation></ref><ref id="R81"><label>81.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kember</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Hartwell</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>H</given-names></name>, <etal/><article-title>Phenome-wide Association Analysis of Substance Use Disorders in a Deeply Phenotyped Sample</article-title>. <source>Biological Psychiatry</source>. doi:<pub-id pub-id-type="doi">10.1016/j.biopsych.2022.08.010</pub-id><pub-id pub-id-type="pmcid">PMC9931661</pub-id><pub-id pub-id-type="pmid">36273948</pub-id></mixed-citation></ref><ref id="R82"><label>82.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pierucci-Lagha</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gelernter</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Feinn</surname><given-names>R</given-names></name>, <etal/><article-title>Diagnostic reliability of the Semistructured Assessment for Drug Dependence and Alcoholism (SSADDA)</article-title>. <source>Drug Alcohol Depend</source>. <year>2005</year>;<volume>80</volume>(<issue>3</issue>):<fpage>303</fpage>&#8211;<lpage>312</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2005.04.005</pub-id><pub-id pub-id-type="pmid">15896927</pub-id></mixed-citation></ref><ref id="R83"><label>83.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pierucci-Lagha</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gelernter</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>G</given-names></name>, <etal/><article-title>Reliability of DSM-IV diagnostic criteria using the semi-structured assessment for drug dependence and alcoholism (SSADDA)</article-title>. <source>Drug Alcohol Depend</source>. <year>2007</year>;<volume>91</volume>(<issue>1</issue>):<fpage>85</fpage>&#8211;<lpage>90</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2007.04.014</pub-id><pub-id pub-id-type="pmid">17590536</pub-id><pub-id pub-id-type="pmcid">PMC2039919</pub-id></mixed-citation></ref><ref id="R84"><label>84.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fuchsberger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Abecasis</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Hinds</surname><given-names>DA</given-names></name>. <article-title>minimac2: faster genotype imputation</article-title>. <source>Bioinformatics</source>. <year>2015</year>;<volume>31</volume>(<issue>5</issue>):<fpage>782</fpage>&#8211;<lpage>784</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btu704</pub-id><pub-id pub-id-type="pmid">25338720</pub-id><pub-id pub-id-type="pmcid">PMC4341061</pub-id></mixed-citation></ref><ref id="R85"><label>85.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Verma</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Damrauer</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Naseer</surname><given-names>N</given-names></name>, <etal/><article-title>The Penn Medicine BioBank: Towards a Genomics-Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse Population</article-title>. <source>Journal of Personalized Medicine</source>. <year>2022</year>;<volume>12</volume>(<issue>12</issue>). doi:<pub-id pub-id-type="doi">10.3390/jpm12121974</pub-id><pub-id pub-id-type="pmcid">PMC9785650</pub-id><pub-id pub-id-type="pmid">36556195</pub-id></mixed-citation></ref><ref id="R86"><label>86.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ge</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Ni</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>YCA</given-names></name>, <name name-style="western"><surname>Smoller</surname><given-names>JW</given-names></name>. <article-title>Polygenic prediction via Bayesian regression and continuous shrinkage priors</article-title>. <source>Nature Communications</source>. <year>2019</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1776</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-09718-5</pub-id><pub-id pub-id-type="pmcid">PMC6467998</pub-id><pub-id pub-id-type="pmid">30992449</pub-id></mixed-citation></ref><ref id="R87"><label>87.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Denny</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Ritchie</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Basford</surname><given-names>MA</given-names></name>, <etal/><article-title>PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene&#8211;disease associations</article-title>. <source>Bioinformatics</source>. <year>2010</year>;<volume>26</volume>(<issue>9</issue>):<fpage>1205</fpage>&#8211;<lpage>1210</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btq126</pub-id><pub-id pub-id-type="pmid">20335276</pub-id><pub-id pub-id-type="pmcid">PMC2859132</pub-id></mixed-citation></ref><ref id="R88"><label>88.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hemani</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Elsworth</surname><given-names>B</given-names></name>, <etal/><article-title>The MR-Base platform supports systematic causal inference across the human phenome</article-title>. <source>Elife</source>. <year>2018</year>;<volume>7</volume>. doi:<pub-id pub-id-type="doi">10.7554/eLife.34408</pub-id><pub-id pub-id-type="pmcid">PMC5976434</pub-id><pub-id pub-id-type="pmid">29846171</pub-id></mixed-citation></ref><ref id="R89"><label>89.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tsepilov</surname><given-names>YA</given-names></name>, <name name-style="western"><surname>Freidin</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Shadrina</surname><given-names>AS</given-names></name>, <etal/><article-title>Analysis of genetically independent phenotypes identifies shared genetic factors associated with chronic musculoskeletal pain conditions</article-title>. <source>Common Biol</source>. <year>2020</year>;<volume>3</volume>(<issue>1</issue>):<fpage>329</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s42003-020-1051-9</pub-id><pub-id pub-id-type="pmcid">PMC7316754</pub-id><pub-id pub-id-type="pmid">32587327</pub-id></mixed-citation></ref><ref id="R90"><label>90.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Valdes</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Abhishek</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Muir</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Maciewicz</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Doherty</surname><given-names>M</given-names></name>. <article-title>Association of Beta-Blocker Use With Less Prevalent Joint Pain and Lower Opioid Requirement in People With Osteoarthritis</article-title>. <source>Arthritis Care Res (Hoboken)</source>. <year>2017</year>;<volume>69</volume>(<issue>7</issue>):<fpage>1076</fpage>&#8211;<lpage>1081</lpage>. doi:<pub-id pub-id-type="doi">10.1002/acr.23091</pub-id><pub-id pub-id-type="pmid">27696728</pub-id></mixed-citation></ref><ref id="R91"><label>91.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nakafero</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Grainge</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Valdes</surname><given-names>AM</given-names></name>, <etal/><article-title>&#946;-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: a propensity score-matched cohort study</article-title>. <source>Rheumatology (Oxford)</source>. <year>2021</year>;<volume>60</volume>(<issue>12</issue>):<fpage>5686</fpage>&#8211;<lpage>5696</lpage>. doi:<pub-id pub-id-type="doi">10.1093/rheumatology/keab234</pub-id><pub-id pub-id-type="pmid">33710319</pub-id><pub-id pub-id-type="pmcid">PMC8645269</pub-id></mixed-citation></ref><ref id="R92"><label>92.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jackson</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Cogbill</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Santana-Davila</surname><given-names>R</given-names></name>, <etal/><article-title>A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache</article-title>. <source>PLOS ONE</source>. <year>2015</year>;<volume>10</volume>(<issue>7</issue>):<fpage>e0130733</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0130733</pub-id><pub-id pub-id-type="pmid">26172390</pub-id><pub-id pub-id-type="pmcid">PMC4501738</pub-id></mixed-citation></ref><ref id="R93"><label>93.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Diatchenko</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Parisien</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jahangiri Esfahani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mogil</surname><given-names>JS</given-names></name>. <article-title>Omics approaches to discover pathophysiological pathways contributing to human pain</article-title>. <source>PAIN</source>. <year>2022</year>;<volume>163</volume>(<issue>S1</issue>). <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.lww.com/pain/Fulltext/2022/11001/Omics_approaches_to_discover_pathophysiological.7.aspx" ext-link-type="uri">https://journals.lww.com/pain/Fulltext/2022/11001/Omics_approaches_to_discover_pathophysiological.7.aspx</ext-link></comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000002726</pub-id><pub-id pub-id-type="pmcid">PMC9557800</pub-id><pub-id pub-id-type="pmid">35994593</pub-id></mixed-citation></ref><ref id="R94"><label>94.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mayr</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jahn</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Stankewitz</surname><given-names>A</given-names></name>, <etal/><article-title>Patients with chronic pain exhibit individually unique cortical signatures of pain encoding</article-title>. <source>Human Brain Mapping</source>. <year>2022</year>;<volume>43</volume>(<issue>5</issue>):<fpage>1676</fpage>&#8211;<lpage>1693</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hbm.25750</pub-id><pub-id pub-id-type="pmid">34921467</pub-id><pub-id pub-id-type="pmcid">PMC8886665</pub-id></mixed-citation></ref><ref id="R95"><label>95.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>CW</given-names></name>. <article-title>Functional brain reconfiguration during sustained pain</article-title>. <name name-style="western"><surname>Ploner</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Behrens</surname><given-names>TE</given-names></name>, <name name-style="western"><surname>Ploner</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Spisak</surname><given-names>T</given-names></name>, eds. <source>eLife</source>. <year>2022</year>;<volume>11</volume>:<fpage>e74463</fpage>. doi:<pub-id pub-id-type="doi">10.7554/eLife.74463</pub-id><pub-id pub-id-type="pmid">36173388</pub-id><pub-id pub-id-type="pmcid">PMC9522250</pub-id></mixed-citation></ref><ref id="R96"><label>96.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Baliki</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Chialvo</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Geha</surname><given-names>PY</given-names></name>, <etal/><article-title>Chronic Pain and the Emotional Brain: Specific Brain Activity Associated with Spontaneous Fluctuations of Intensity of Chronic Back Pain</article-title>. <source>J Neurosci</source>. <year>2006</year>;<volume>26</volume>(<issue>47</issue>):<fpage>12165</fpage>. doi:<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3576-06.2006</pub-id><pub-id pub-id-type="pmid">17122041</pub-id><pub-id pub-id-type="pmcid">PMC4177069</pub-id></mixed-citation></ref><ref id="R97"><label>97.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bortsov</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Parisien</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Khoury</surname><given-names>S</given-names></name>, <etal/><article-title>Brain-specific genes contribute to chronic but not to acute back pain</article-title>. <source>PAIN Reports</source>. <year>2022</year>;<volume>7</volume>(<issue>5</issue>). <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.lww.com/painrpts/Fulltext/2022/10000/Brain_specific_genes_contribute_to_chronic_but_not.6.aspx" ext-link-type="uri">https://journals.lww.com/painrpts/Fulltext/2022/10000/Brain_specific_genes_contribute_to_chronic_but_not.6.aspx</ext-link></comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PR9.0000000000001018</pub-id><pub-id pub-id-type="pmcid">PMC9371560</pub-id><pub-id pub-id-type="pmid">35975136</pub-id></mixed-citation></ref><ref id="R98"><label>98.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Khoury</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Parisien</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>SJ</given-names></name>, <etal/><article-title>Genome-wide analysis identifies impaired axonogenesis in chronic overlapping pain conditions</article-title>. <source>Brain</source>. <year>2022</year>;<volume>145</volume>(<issue>3</issue>):<fpage>1111</fpage>&#8211;<lpage>1123</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awab359</pub-id><pub-id pub-id-type="pmid">34788396</pub-id></mixed-citation></ref><ref id="R99"><label>99.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Enna</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>McCarson</surname><given-names>KE</given-names></name>. <article-title>The role of GABA in the mediation and perception of pain</article-title>. <source>Adv Pharmacol</source>. <year>2006</year>;<volume>54</volume>:<fpage>1</fpage>&#8211;<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1054-3589(06)54001-3</pub-id><pub-id pub-id-type="pmid">17175808</pub-id></mixed-citation></ref><ref id="R100"><label>100.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Goudet</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Magnaghi</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Landry</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nagy</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gereau</surname><given-names>RW</given-names><suffix>4th</suffix></name>, <name name-style="western"><surname>Pin</surname><given-names>JP</given-names></name>. <article-title>Metabotropic receptors for glutamate and GABA in pain</article-title>. <source>Brain Res Rev</source>. <year>2009</year>;<volume>60</volume>(<issue>1</issue>):<fpage>43</fpage>&#8211;<lpage>56</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.brainresrev.2008.12.007</pub-id><pub-id pub-id-type="pmid">19146876</pub-id></mixed-citation></ref><ref id="R101"><label>101.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dong</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Allocco</surname><given-names>A</given-names></name>, <etal/><article-title>Exome Sequencing Implicates Impaired GABA Signaling and Neuronal Ion Transport in Trigeminal Neuralgia</article-title>. <source>iScience</source>. <year>2020</year>;<volume>23</volume>(<issue>10</issue>):<fpage>101552</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.isci.2020.101552</pub-id><pub-id pub-id-type="pmid">33083721</pub-id><pub-id pub-id-type="pmcid">PMC7554653</pub-id></mixed-citation></ref><ref id="R102"><label>102.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Xie</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name>, <etal/><article-title>Divergent modulation of pain and anxiety by GABAergic neurons in the ventrolateral periaqueductal gray and dorsal raphe</article-title>. <source>Neuropsychopharmacology</source>. Published online <month>December</month><day>16</day>, <year>2022</year>. doi:<pub-id pub-id-type="doi">10.1038/s41386-022-01520-0</pub-id><pub-id pub-id-type="pmcid">PMC10425368</pub-id><pub-id pub-id-type="pmid">36526697</pub-id></mixed-citation></ref><ref id="R103"><label>103.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bridge</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Stagg</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Near</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>C ieong</given-names></name>, <name name-style="western"><surname>Zisner</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cader</surname><given-names>MZ</given-names></name>. <article-title>Altered neurochemical coupling in the occipital cortex in migraine with visual aura</article-title>. <source>Cephalalgia</source>. <year>2015</year>;<volume>35</volume>(<issue>11</issue>):<fpage>1025</fpage>&#8211;<lpage>1030</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0333102414566860</pub-id><pub-id pub-id-type="pmid">25631169</pub-id></mixed-citation></ref><ref id="R104"><label>104.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Foerster</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Petrou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Edden</surname><given-names>RAE</given-names></name>, <etal/><article-title>Reduced insular &#947;-aminobutyric acid in fibromyalgia</article-title>. <source>Arthritis Rheum</source>. <year>2012</year>;<volume>64</volume>(<issue>2</issue>):<fpage>579</fpage>&#8211;<lpage>583</lpage>. doi:<pub-id pub-id-type="doi">10.1002/art.33339</pub-id><pub-id pub-id-type="pmid">21913179</pub-id><pub-id pub-id-type="pmcid">PMC3374930</pub-id></mixed-citation></ref><ref id="R105"><label>105.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <etal/><article-title>Elevated GABA level in the precuneus and its association with pain intensity in patients with postherpetic neuralgia: An initial proton magnetic resonance spectroscopy study</article-title>. <source>Eur J Radiol</source>. <year>2022</year>;<volume>157</volume>:<fpage>110568</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejrad.2022.110568</pub-id><pub-id pub-id-type="pmid">36279626</pub-id></mixed-citation></ref><ref id="R106"><label>106.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Naik</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Pathirathna</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jevtovic-Todorovic</surname><given-names>V</given-names></name>. <article-title>GABAA receptor modulation in dorsal root ganglia in vivo affects chronic pain after nerve injury</article-title>. <source>Neuroscience</source>. <year>2008</year>;<volume>154</volume>(<issue>4</issue>):<fpage>1539</fpage>&#8211;<lpage>1553</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.04.061</pub-id><pub-id pub-id-type="pmid">18554816</pub-id></mixed-citation></ref><ref id="R107"><label>107.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Jose</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>C</given-names></name>. <article-title>Comprehensive insights in GRK4 and hypertension: From mechanisms to potential therapeutics</article-title>. <source>Pharmacology &amp; Therapeutics</source>. <year>2022</year>;<volume>239</volume>:<fpage>108194</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pharmthera.2022.108194</pub-id><pub-id pub-id-type="pmid">35487286</pub-id><pub-id pub-id-type="pmcid">PMC9728143</pub-id></mixed-citation></ref><ref id="R108"><label>108.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Olsen</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Bruehl</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Rosseland</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Eggen</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Stubhaug</surname><given-names>A</given-names></name>. <article-title>Hypertension prevalence and diminished blood pressure&#8211;related hypoalgesia in individuals reporting chronic pain in a general population: The Troms&#248; Study</article-title>. <source>PAIN</source>. <year>2013</year>;<volume>154</volume>(<issue>2</issue>). <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.lww.com/pain/Fulltext/2013/02000/Hypertension_prevalence_and_diminished_blood.15.aspx" ext-link-type="uri">https://journals.lww.com/pain/Fulltext/2013/02000/Hypertension_prevalence_and_diminished_blood.15.aspx</ext-link></comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2012.10.020</pub-id><pub-id pub-id-type="pmid">23245863</pub-id></mixed-citation></ref><ref id="R109"><label>109.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>YC</given-names></name>. <article-title>Prevalence of pain in community-dwelling older adults with hypertension in the United States</article-title>. <source>Scientific Reports</source>. <year>2022</year>;<volume>12</volume>(<issue>1</issue>):<fpage>8387</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-022-12331-0</pub-id><pub-id pub-id-type="pmid">35589916</pub-id><pub-id pub-id-type="pmcid">PMC9119929</pub-id></mixed-citation></ref><ref id="R110"><label>110.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Geisheker</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Heymann</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>T</given-names></name>, <etal/><article-title>Hotspots of missense mutation identify neurodevelopmental disorder genes and functional domains</article-title>. <source>Nature Neuroscience</source>. <year>2017</year>;<volume>20</volume>(<issue>8</issue>):<fpage>1043</fpage>&#8211;<lpage>1051</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nn.4589</pub-id><pub-id pub-id-type="pmid">28628100</pub-id><pub-id pub-id-type="pmcid">PMC5539915</pub-id></mixed-citation></ref><ref id="R111"><label>111.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ismail</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Zachariassen</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Godwin</surname><given-names>A</given-names></name>, <etal/><article-title>Identification and functional evaluation of GRIA1 missense and truncation variants in individuals with ID: An emerging neurodevelopmental syndrome</article-title>. <source>The American Journal of Human Genetics</source>. <year>2022</year>;<volume>109</volume>(<issue>7</issue>):<fpage>1217</fpage>&#8211;<lpage>1241</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajhg.2022.05.009</pub-id><pub-id pub-id-type="pmid">35675825</pub-id><pub-id pub-id-type="pmcid">PMC9300760</pub-id></mixed-citation></ref><ref id="R112"><label>112.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Aranke</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pham</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Yilmaz</surname><given-names>M</given-names></name>, <etal/><article-title>Topical Sevoflurane: A Novel Treatment for Chronic Pain Caused by Venous Stasis Ulcers</article-title>. <source>Anesth Pain Med</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>e112832</fpage>. doi:<pub-id pub-id-type="doi">10.5812/aapm.112832</pub-id><pub-id pub-id-type="pmid">34221949</pub-id><pub-id pub-id-type="pmcid">PMC8241821</pub-id></mixed-citation></ref><ref id="R113"><label>113.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Finnerup</surname><given-names>NB</given-names></name>, <name name-style="western"><surname>Attal</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Haroutounian</surname><given-names>S</given-names></name>, <etal/><article-title>Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis</article-title>. <source>The Lancet Neurology</source>. <year>2015</year>;<volume>14</volume>(<issue>2</issue>):<fpage>162</fpage>&#8211;<lpage>173</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(14)70251-0</pub-id><pub-id pub-id-type="pmid">25575710</pub-id><pub-id pub-id-type="pmcid">PMC4493167</pub-id></mixed-citation></ref><ref id="R114"><label>114.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Khan</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Hah</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Mackey</surname><given-names>SC</given-names></name>. <article-title>Effects of smoking on patients with chronic pain: a propensity-weighted analysis on the Collaborative Health Outcomes Information Registry</article-title>. <source>PAIN</source>. <year>2019</year>;<volume>160</volume>(<issue>10</issue>). <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.lww.com/pain/Fulltext/2019/10000/Effects_of_smoking_on_patients_with_chronic_pain_.22.aspx" ext-link-type="uri">https://journals.lww.com/pain/Fulltext/2019/10000/Effects_of_smoking_on_patients_with_chronic_pain_.22.aspx</ext-link></comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000001631</pub-id><pub-id pub-id-type="pmcid">PMC6768701</pub-id><pub-id pub-id-type="pmid">31149975</pub-id></mixed-citation></ref><ref id="R115"><label>115.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nicholas</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vlaeyen</surname><given-names>JWS</given-names></name>, <name name-style="western"><surname>Rief</surname><given-names>W</given-names></name>, <etal/><article-title>The IASP classification of chronic pain for ICD-11: chronic primary pain</article-title>. <source>Pain</source>. <year>2019</year>;<volume>160</volume>(<issue>1</issue>):<fpage>28</fpage>&#8211;<lpage>37</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000001390</pub-id><pub-id pub-id-type="pmid">30586068</pub-id></mixed-citation></ref><ref id="R116"><label>116.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Goulet</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Brandt</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Crystal</surname><given-names>S</given-names></name>, <etal/><article-title>Agreement between electronic medical record-based and self-administered pain numeric rating scale: clinical and research implications</article-title>. <source>Med Care</source>. <year>2013</year>;<volume>51</volume>(<issue>3</issue>):<fpage>245</fpage>&#8211;<lpage>250</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MLR.0b013e318277f1ad</pub-id><pub-id pub-id-type="pmid">23222528</pub-id><pub-id pub-id-type="pmcid">PMC3572341</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><title>Manhattan plot for the pain intensity cross-ancestry GWAS meta-analysis.</title><p id="P75">This identified 125 independent index variants. SNPs above the red line are GWS after correction for multiple testing (<italic toggle="yes">P</italic> &lt; 5 &#215; 10<sup>&#8722;8</sup>)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2023.03.09.23286958v1-f0001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><title>Enrichment of pain intensity in the brain.</title><p id="P76"><bold>A,</bold> Partitioning heritability enrichment analyses using LDSC showing enrichment for pain intensity in the CNS, adrenal, liver, cardiovascular, and skeletal tissues. The dashed black lines indicate Bonferroni-corrected significance (<italic toggle="yes">P</italic> &lt; 0.005). <bold>B</bold>, Proportion of heritability shows robust enrichment for SNPs in brain and immune-related tissues. Heritability enrichment analyses for gene expression (<bold>C &amp; D</bold>) and chromatin interaction (top 35 annotations are shown in <bold>E,</bold> see <xref rid="SD2" ref-type="supplementary-material">supplementary Table 12</xref> for full details) using GTEx data show enrichment for pain intensity in brain regions previously associated with chronic pain. Bonferroni correction was applied within each tissue conditioned on the number of genes tested.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2023.03.09.23286958v1-f0002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><title>Gene prioritization for pain intensity.</title><p id="P77"><bold>A,</bold> Genomic annotation of credible sets using FINEMAP shows enrichment largely in non-coding regions and to a lesser extent in exons. <bold>B</bold>, Annotation of known and novel credible genes. Dashed lines indicate posterior probability &gt; 0.5. <bold>C</bold>, Number of overlapping genes across functional prediction models. <bold>D</bold>, Tissue enrichment of prioritized genes using SMR and GTEx data show enrichment in brain regions. Size of circle reflects &#8722;log<sub>10</sub><italic toggle="yes">P</italic>. Bonferroni correction was applied within each tissue conditioned on the number of genes tested.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2023.03.09.23286958v1-f0003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><title>Genetic correlation and drug repurposing.</title><p id="P78"><bold>A,</bold> Genetic correlation for pain intensity using LDSC. All points passing Bonferroni correction (Bonferroni correction threshold = 5.62 &#215; 10<sup>&#8722;4</sup> [0.05/89]) are plotted. The color of the circle indicates the phenotypic category. <bold>B</bold>, Druggable targets and drug interactions for 8 credible genes associated with pain intensity. For a full list of credible drug targets see <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 30</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2023.03.09.23286958v1-f0004.jpg"/></fig></floats-group></article></pmc-articleset>